var title_f35_63_36848="Medial directed cecum";
var content_f35_63_36848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contrast enema demonstrating a medially directed cecum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This contrast enema illustrates the high, medially directed cecum (see arrow) that can be seen in malrotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright &copy; Carlo Buonomo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36848=[""].join("\n");
var outline_f35_63_36848=null;
var title_f35_63_36849="Corneal ulcers";
var content_f35_63_36849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal infiltrates or ulcers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two small corneal white spots that are either infiltrates or ulcers (indicated by the arrows) are shown with normal light illumination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36849=[""].join("\n");
var outline_f35_63_36849=null;
var title_f35_63_36850="Evaluation for hyperandrogenism risk factors";
var content_f35_63_36850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Initial evaluation for the presence of hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 689px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Suggested algorithm for the initial evaluation of young women for hyperandrogenism, based on The Endocrine Society clinical practice guidelines for the evaluation of hirsutism. Risk assessment includes more than the degree of hirsutism. Focal hirsutism that is not accompanied by hyperandrogenism risk factors does not require an endocrine workup. If hirsutism is of an abnormal degree (Ferriman-Gallwey score &ge;8 in the&nbsp;general US population) or if a risk factor assessment suggests an underlying disorder, elevated androgen levels should be ruled out. Disorders to be considered, as shown, include neoplasm and various endocrinopathies, of which PCOS is the most common;&nbsp;if an abdominal or pelvic mass is palpable, a prompt screening ultrasound is advisable. Drugs that cause hirsutism include anabolic or androgenic steroids (consider in athletes), most of which are not detected by testosterone assays, and valproic acid (consider in neurologic disorders), which elevates serum testosterone.&nbsp;Serum testosterone is best assessed by an&nbsp;analytically specific&nbsp;method, such as mass spectrometry, preferably in the early morning. Females with mild hirsutism (score 8 to 15 in the general US population), normal total testosterone level, and no risk factors probably have idiopathic hirsutism, which may be responsive to oral contraceptive therapy. The calculated free testosterone level is the most clinically sensitive marker of androgen excess and should be assayed in a reference laboratory if the total testosterone is normal in the presence of risk factors or if signs or symptoms progress on therapy. Simultaneous assay of 17-hydroxyprogesterone may be indicated in subjects at risk for congenital adrenal hyperplasia, eg, Ashkenazi Jews.",
"    <div class=\"footnotes\">",
"     PCOS: polycystic ovary syndrome; SHBG: sex hormone binding globulin.",
"     <br>",
"      * The free testosterone level in blood is ordinarily calculated&nbsp;as the product of the total testosterone level and the percent free testosterone, which&nbsp;may be&nbsp;computed from the SHBG level. Norms are standardized for early morning in the early follicular phase (days 4 to 10) of the menstrual cycle.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Progression of hyperandrogenism in the presence of a normal serum free testosterone is very unusual. Such patients should be thoroughly re-evaluated.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and expanded from: Martin KA, Change J, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36850=[""].join("\n");
var outline_f35_63_36850=null;
var title_f35_63_36851="LAV hysterectomy PI";
var content_f35_63_36851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Laparoscopically assisted vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In laparoscopic-assisted vaginal hysterectomy, three small incisions are made in the abdomen. The laparascope is inserted through these incisions. The uterus and cervix are removed through the vagina. The top of the vagina is then sewn together. The ovaries and fallopian tubes may also be removed (called salpingo-oophorectomy) at the same time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36851=[""].join("\n");
var outline_f35_63_36851=null;
var title_f35_63_36852="Neomycin: Patient drug information";
var content_f35_63_36852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     see \"Neomycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     see \"Neomycin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse and hearing loss, and it may change your sense of balance. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop infections during bowel surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the signs of hepatic coma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3019660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Crohn's disease, bowel block, or ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ear problems with a hearing loss or loss of balance, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, myasthenia disease, or other nerve problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11371 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36852=[""].join("\n");
var outline_f35_63_36852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015561\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015563\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015562\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015567\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015568\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015570\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015565\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015566\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015571\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015572\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=related_link\">",
"      Neomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=related_link\">",
"      Neomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36853="Hormones in THCD";
var content_f35_63_36853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Serum hormone concentrations in patients with MCT8 defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thyroid function tests from seven families studied at the University of Chicago: 11 affected males (M: red squares), 15 carrier females (F: green circles), and 15 unaffected family members (N: blue triangles). (* P &lt;0.05; ** P &lt;0.01; *** P &lt;0.001). Shaded areas represent the normal range for each test. Bars are 2 SDs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36853=[""].join("\n");
var outline_f35_63_36853=null;
var title_f35_63_36854="Epidemiology and pathophysiology of colonic diverticular disease";
var content_f35_63_36854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathophysiology of colonic diverticular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Tonia Young-Fadok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     John H Pemberton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36854/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/63/36854/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticular disease of the colon is common. This topic review will focus on the epidemiology and pathophysiology of the disorder. It is useful to begin with a series of definitions of the terms that are commonly used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diverticulum is a sac-like protrusion of the colonic wall.",
"     </li>",
"     <li>",
"      Diverticulosis merely describes the presence of diverticula.",
"     </li>",
"     <li>",
"      Diverticulitis refers to inflammation of diverticula.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diverticular disease is a term encompassing diverticulosis and diverticulitis. Symptomatic diverticular disease includes hemorrhage, inflammation (diverticulitis), or complications of diverticulitis such as abscess, fistula, obstruction, or free perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticular disease was uncommonly encountered at the beginning of the twentieth century. The first report of surgical resection for complicated diverticulitis was by Mayo in 1907 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of diverticular disease is age-dependent, increasing from less than 20 percent at age 40, to 60 percent by age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A nationwide inpatient study of hospitalizations in the United States showed an increase of 26 percent in admissions for acute diverticulitis from 1998 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/4\">",
"     4",
"    </a>",
"    ]. The largest increase (82 percent) was in patients aged 18 to 44 years. Elective operations for diverticulitis also increased by 29 percent with the most rapid increase (73 percent) in patients aged 18 to 44 years.",
"   </p>",
"   <p>",
"    A male preponderance was noted in early series, but other studies have suggested either equal distribution or a female preponderance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/5\">",
"     5",
"    </a>",
"    ]. This may be explained by a gender distribution which varies with age; in one series, men were more often affected under age 50, there was a slight female preponderance between the ages of 50 and 70, and a marked female preponderance over age 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/6\">",
"     6",
"    </a>",
"    ]. An excess number of males has also been noted for acute diverticulitis in patients under 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are geographic variations in both the prevalence and pattern of diverticulosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Westernized\" nations have prevalence rates of 5 to 45 percent, depending upon the method of diagnosis and age of the population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Diverticular disease in these countries is predominantly",
"      <strong>",
"       left-sided",
"      </strong>",
"      , with right-sided diverticulitis being present in only 1.5 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The findings are different in Asia, where the prevalence is between &lt;1 and 5 per million population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/12\">",
"       12",
"      </a>",
"      ], and diverticulosis is usually",
"      <strong>",
"       right-sided",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Japan, after adopting a more Western lifestyle, has experienced an increase in the prevalence of right-sided diverticulosis. In one report of 615 patients with colonic diverticular disease, right-sided diverticula were present in approximately 70 percent of all patients and were responsible for approximately 75 percent of cases of diverticulitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/14\">",
"       14",
"      </a>",
"      ]. A review of 13,947",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema examinations performed over a 15-year period in Japan revealed a steady increase in the incidence of diverticulosis of the right colon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/15\">",
"       15",
"      </a>",
"      ]. Left-sided diverticula did not increase in frequency over time. The increase in the incidence of right-sided diverticula in Japan is similar to the increase in the incidence of left-sided diverticula in westernized countries. A right-sided predominance has also been noted in Singapore, where 70 percent of cases occur in patients less than 40 years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/16\">",
"       16",
"      </a>",
"      ], and in Hong Kong [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in incidence in the developed nations suggests environmental and lifestyle factors play an important role in the pathogenesis of diverticular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dietary fiber intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that low dietary fiber predisposes to the development of diverticular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ] although this hypothesis has not been confirmed in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. One report that evaluated a cohort of over 47,000 men provided strong evidence for the role of dietary fiber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/20\">",
"     20",
"    </a>",
"    ]. After adjustment for age, energy-adjusted total fat intake, and physical activity, total dietary fiber intake was noted to be inversely associated with the risk of symptomatic diverticular disease. The relative risk was 0.58 for men in the highest quintile compared to those in the lowest quintile for fiber intake. The observation that diverticular disease is less common in vegetarians than nonvegetarians is also compatible with a role for dietary fiber, since vegetables and fruits are important sources of fiber (",
"    <a class=\"graphic graphic_table graphicRef60358 \" href=\"mobipreview.htm?7/48/7949\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If it is beneficial, dietary fiber may act by producing a large bulky stool, resulting in a wider-bore colon that is less likely to permit efficient segmentation and therefore less likely to develop diverticula (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Pathophysiology of diverticula formation'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, increasing dietary fiber is often used as first-line therapy for treatment of constipation. However, there is no clear correlation between constipation and diverticular disease, probably stemming from the retrospective nature of most studies and the difficulties in defining constipation in a large series of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other dietary factors that might contribute to the pathogenesis of diverticular disease have been examined. There is",
"    <strong>",
"     no",
"    </strong>",
"    substantially increased risk associated with smoking, caffeine, or alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/28\">",
"     28",
"    </a>",
"    ]. On the other hand, an association has been noted between obesity in men under 40 years and acute diverticulitis. This finding is compatible with observations that the risk of symptomatic diverticular disease is particularly increased (relative risk 2.35 to 3.32) by a diet characterized by a high intake of total fat or red meat and a low intake of dietary fiber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/20\">",
"     20",
"    </a>",
"    ]. Issues related so consumption of seeds and nuts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13450?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of acute diverticulitis\", section on 'Seeds and nuts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of vigorous exercise also may be a risk factor for diverticular disease. In a prospective study of almost 48,000 American men aged 40 to 75 who were free of known colonic disease, the risk of developing symptomatic diverticular disease was inversely related to overall physical activity (0.63 for highest versus lowest extremes) after adjustment for age and dietary fat and fiber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/29\">",
"     29",
"    </a>",
"    ]. Most of the decrease in risk with exercise was associated with vigorous activity such as jogging and running. An interaction was noted between physical activity and dietary fiber; men in the lowest quintile for both had a relative risk of 2.56 compared to men in the highest quintile for both. How physical activity might prevent diverticular disease is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has been linked to the development of diverticulitis and diverticular bleeding in several reports. In a large, prospective cohort study, for example, there were 801 incident cases of diverticulitis and 383 cases of diverticular bleeding during 18 years of follow-up in a cohort of 47,228 male health professionals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/30\">",
"     30",
"    </a>",
"    ]. The relative risk of diverticulitis in those with the highest quintile of waist circumference was 1.56 (95% CI 1.18-2.07). A similar increase was noted for diverticular bleeding (RR 1.96, 95% CI 1.30-2.97).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Possible relation with colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may also be a relation between diverticulosis and colon cancer. One series of 7000 patients found an excess number of colon and rectal cancers in the first two years after the diagnosis of diverticular disease but not with more prolonged follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/31\">",
"     31",
"    </a>",
"    ]. There was, however, a long-term excess of left-sided colon cancers, suggesting a possible relation between these tumors and diverticular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical colonic diverticulum is a \"false\" or pulsion diverticulum, eg, it does not contain all layers of the wall as a true (congenital) diverticulum does; instead, mucosa and submucosa herniate through the muscle layer, covered only by serosa (",
"    <a class=\"graphic graphic_picture graphicRef69797 \" href=\"mobipreview.htm?3/8/3206\">",
"     picture 1",
"    </a>",
"    ). Diverticula develop at four well-defined points around the circumference of the colon, sites at which the vasa recta penetrate the circular muscle layer. These vessels enter the wall on each side of the mesenteric taenia and on the mesenteric border of the two antimesenteric taeniae (",
"    <a class=\"graphic graphic_figure graphicRef62942 \" href=\"mobipreview.htm?18/21/18771\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diverticula are distributed unevenly in the colon. Ninety-five percent of patients have sigmoid diverticula, while 35 percent also have more proximal disease. Among the latter group, 7 percent have diverticula throughout the colon, and 4 percent have diverticula limited to a segment proximal to the sigmoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/32\">",
"     32",
"    </a>",
"    ]. The location of diverticular disease requiring surgery is similar, with 95 percent of all operative cases involving the sigmoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF DIVERTICULA FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The points at which diverticula develop, eg, where vasa recta penetrate the bowel wall, are considered areas of weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/33\">",
"     33",
"    </a>",
"    ]. Most patients with sigmoid diverticula exhibit mycosis, which consists of thickening of the circular muscle layer, shortening of the taeniae, and luminal narrowing. There is no hypertrophy or hyperplasia of the bowel wall, but increased elastin deposition is found in the taeniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/34\">",
"     34",
"    </a>",
"    ]. There are also structural changes in collagen that are similar to, but greater in magnitude than, those that occur because of aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes may decrease resistance of the wall to intraluminal pressure. Structural changes in the wall may also be responsible for the appearance of diverticula at an early age in connective tissue disorders such as Ehlers-Danlos and Marfan's syndromes and in autosomal dominant polycystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The law of Laplace explains the development of diverticula. The law states that pressure P is proportional to wall tension T, and inversely proportional to bowel radius R:",
"   </p>",
"   <p>",
"    &nbsp;P = kT &divide; R",
"   </p>",
"   <p>",
"    where k is a conversion factor. Since the sigmoid colon is the segment of the colon with the smallest diameter, it will tend to be the site of the highest pressure. This is not true under normal circumstances because pressure should be the same throughout the colon. However, segmentation of the colon (a motility process in which segmental muscular contractions separate the lumen into chambers) is exaggerated in diverticulosis, occluding both ends of the chamber during muscular contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/37\">",
"     37",
"    </a>",
"    ]. This increases intraluminal pressure and may predispose to herniation of mucosa. The neural basis for the abnormal motility observed in patients with diverticulosis remains unclear. One report found that a central event appeared to be upregulation of smooth muscle M3 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, abnormal colonic motility may predispose to the development of diverticula. It has been suggested that dietary fiber, by producing a large bulky stool, results in a wider-bore colon that is less likely to permit efficient segmentation and therefore less likely to develop diverticula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathophysiology of diverticulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulitis, eg, inflammation of diverticula, produces variable clinical manifestations, ranging from subclinical inflammation to generalized peritonitis. The underlying cause is micro- or macroscopic",
"    <strong>",
"     perforation",
"    </strong>",
"    of a diverticulum. It was previously believed that obstruction of diverticula, eg, by fecaliths, increased diverticular pressure and caused perforation; such obstruction is now thought to be rare (",
"    <a class=\"graphic graphic_picture graphicRef80763 \" href=\"mobipreview.htm?5/3/5168\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69797 \" href=\"mobipreview.htm?3/8/3206\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/21\">",
"     21",
"    </a>",
"    ]. The primary process is thought to be erosion of the diverticular wall by increased intraluminal pressure or inspissated food particles. Inflammation and focal necrosis ensue, resulting in perforation.",
"   </p>",
"   <p>",
"    The inflammation is frequently mild, and a small perforation is walled off by pericolic fat and mesentery. This may lead to a localized abscess or, if adjacent organs are involved, a fistula or obstruction. In comparison, poor containment results in free perforation and peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathophysiology of diverticular bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a diverticulum herniates, the penetrating vessel responsible for the wall weakness at that point becomes draped over the dome of the diverticulum, separated from the bowel lumen only by mucosa (",
"    <a class=\"graphic graphic_picture graphicRef52254 \" href=\"mobipreview.htm?18/51/19252\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/33\">",
"     33",
"    </a>",
"    ]. Over time, the vasa recta is exposed to injury along its luminal aspect, leading to eccentric intimal thickening and thinning of the media. These changes may result in segmental weakness of the artery, predisposing to rupture into the lumen. Diverticular bleeding typically occurs in the absence of diverticulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anatomic relationship between diverticula and vasa recta is similar in both the right and left colon; however, right-sided diverticula have wider necks and domes. This could expose the vasa recta to injury over a greater length, which could explain the higher incidence of right-sided hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36854/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/6/1122?source=see_link\">",
"       \"Patient information: Diverticulitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=see_link\">",
"       \"Patient information: Diverticular disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticula occur at points of weakness in the bowel wall where blood vessels penetrate. The development of diverticula is probably multifactorial, involving both increases in intraluminal pressure and abnormalities in the bowel wall. Raised intraluminal pressure may be caused by abnormalities in motility that predispose to segmentation, and is likely to be exacerbated by a low fiber diet.",
"   </p>",
"   <p>",
"    Histologic changes in the muscle and collagen of the bowel wall decrease the tensile strength of the wall; these changes are similar to, but more pronounced than, the changes that occur with age. Trauma to diverticula may produce either inflammation, which results in perforation, or changes in the vasa recta in the diverticular wall, which predisposes to weakness and rupture of the vessel.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/1\">",
"      Mayo, WJ, Wilson, LB, Giffin, HZ. Acquired diverticulitis of the large intestine. Surg Gynecol Obstet 1907; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/2\">",
"      Painter NS, Burkitt DP. Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 1975; 4:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/3\">",
"      Peery AF, Barrett PR, Park D, et al. A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology 2012; 142:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/4\">",
"      Etzioni DA, Mack TM, Beart RW Jr, Kaiser AM. Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment. Ann Surg 2009; 249:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/5\">",
"      Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/6\">",
"      Rodkey GV, Welch CE. Changing patterns in the surgical treatment of diverticular disease. Ann Surg 1984; 200:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/7\">",
"      Acosta JA, Grebenc ML, Doberneck RC, et al. Colonic diverticular disease in patients 40 years old or younger. Am Surg 1992; 58:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/8\">",
"      Schauer PR, Ramos R, Ghiatas AA, Sirinek KR. Virulent diverticular disease in young obese men. Am J Surg 1992; 164:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/9\">",
"      Hughes LE. Postmortem survey of diverticular disease of the colon. I. Diverticulosis and diverticulitis. Gut 1969; 10:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/10\">",
"      Manousos ON, Truelove SC, Lumsden K. Prevalence of colonic diverticulosis in general population of Oxford area. Br Med J 1967; 3:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/11\">",
"      Fischer MG, Farkas AM. Diverticulitis of the cecum and ascending colon. Dis Colon Rectum 1984; 27:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/12\">",
"      Delvaux M. Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. Aliment Pharmacol Ther 2003; 18 Suppl 3:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/13\">",
"      Chan CC, Lo KK, Chung EC, et al. Colonic diverticulosis in Hong Kong: distribution pattern and clinical significance. Clin Radiol 1998; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/14\">",
"      Sugihara K, Muto T, Morioka Y, et al. Diverticular disease of the colon in Japan. A review of 615 cases. Dis Colon Rectum 1984; 27:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/15\">",
"      Miura S, Kodaira S, Shatari T, et al. Recent trends in diverticulosis of the right colon in Japan: retrospective review in a regional hospital. Dis Colon Rectum 2000; 43:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/16\">",
"      Ngoi SS, Chia J, Goh MY, et al. Surgical management of right colon diverticulitis. Dis Colon Rectum 1992; 35:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/17\">",
"      Markham NI, Li AK. Diverticulitis of the right colon--experience from Hong Kong. Gut 1992; 33:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/18\">",
"      Lo CY, Chu KW. Acute diverticulitis of the right colon. Am J Surg 1996; 171:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/19\">",
"      Painter NS. The cause of diverticular disease of the colon, its symptoms and its complications. Review and hypothesis. J R Coll Surg Edinb 1985; 30:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/20\">",
"      Aldoori WH, Giovannucci EL, Rimm EB, et al. A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr 1994; 60:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/21\">",
"      Rege RV, Nahrwold DL. Diverticular disease. Curr Probl Surg 1989; 26:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/22\">",
"      Talbot JM. Role of dietary fiber in diverticular disease and colon cancer. Fed Proc 1981; 40:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/23\">",
"      Mendeloff, AI. A critique of \"fiber deficiency\". Dig Dis 1976; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/24\">",
"      Ornstein MH, Littlewood ER, Baird IM, et al. Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed) 1981; 282:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/25\">",
"      Brodribb AJ. Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1977; 1:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/26\">",
"      Hodgson WJ. The placebo effect. Is it important in diverticular disease? Am J Gastroenterol 1977; 67:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/27\">",
"      Nair P, Mayberry JF. Vegetarianism, dietary fibre and gastro-intestinal disease. Dig Dis 1994; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/28\">",
"      Aldoori WH, Giovannucci EL, Rimm EB, et al. A prospective study of alcohol, smoking, caffeine, and the risk of symptomatic diverticular disease in men. Ann Epidemiol 1995; 5:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/29\">",
"      Aldoori WH, Giovannucci EL, Rimm EB, et al. Prospective study of physical activity and the risk of symptomatic diverticular disease in men. Gut 1995; 36:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/30\">",
"      Strate LL, Liu YL, Aldoori WH, et al. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology 2009; 136:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/31\">",
"      Stef&aacute;nsson T, Ekbom A, Spar&egrave;n P, P&aring;hlman L. Increased risk of left sided colon cancer in patients with diverticular disease. Gut 1993; 34:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/32\">",
"      Parks TG. Natural history of diverticular disease of the colon. A review of 521 cases. Br Med J 1969; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/33\">",
"      Meyers MA, Alonso DR, Gray GF, Baer JW. Pathogenesis of bleeding colonic diverticulosis. Gastroenterology 1976; 71:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/34\">",
"      Whiteway J, Morson BC. Elastosis in diverticular disease of the sigmoid colon. Gut 1985; 26:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/35\">",
"      Wess L, Eastwood MA, Wess TJ, et al. Cross linking of collagen is increased in colonic diverticulosis. Gut 1995; 37:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/36\">",
"      Scheff RT, Zuckerman G, Harter H, et al. Diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Ann Intern Med 1980; 92:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/37\">",
"      PAINTER NS, TRUELOVE SC, ARDRAN GM, TUCKEY M. SEGMENTATION AND THE LOCALIZATION OF INTRALUMINAL PRESSURES IN THE HUMAN COLON, WITH SPECIAL REFERENCE TO THE PATHOGENESIS OF COLONIC DIVERTICULA. Gastroenterology 1965; 49:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36854/abstract/38\">",
"      Golder M, Burleigh DE, Belai A, et al. Smooth muscle cholinergic denervation hypersensitivity in diverticular disease. Lancet 2003; 361:1945.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1379 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-F656983DA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36854=[""].join("\n");
var outline_f35_63_36854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dietary fiber intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other dietary factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Possible relation with colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LOCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY OF DIVERTICULA FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathophysiology of diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathophysiology of diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1379|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/21/18771\" title=\"figure 1\">",
"      Location colonic diverticula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1379|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/8/3206\" title=\"picture 1\">",
"      Diverticulosis fecolith",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/3/5168\" title=\"picture 2\">",
"      Divertic with fecolith Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/51/19252\" title=\"picture 3\">",
"      Bleeding diverticulum endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/48/7949\" title=\"table 1\">",
"      Fiber content of food",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38679?source=related_link\">",
"      Colonic diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=related_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/6/1122?source=related_link\">",
"      Patient information: Diverticulitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13450?source=related_link\">",
"      Treatment of acute diverticulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36855="Congenital rubella syndrome: Management, outcome, and prevention";
var content_f35_63_36855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital rubella syndrome: Management, outcome, and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Simon R Dobson, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36855/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/63/36855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management, outcome, and prevention of congenital rubella syndrome will be discussed here. The epidemiology of rubella infection, risk of rubella-associated congenital defects, and the clinical features and diagnosis of congenital rubella infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital rubella infection &mdash; Congenital rubella infection (CRI) encompasses all outcomes associated with intrauterine rubella infection (ie, miscarriage, stillbirth, combinations of birth defects, asymptomatic infection) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital rubella syndrome &mdash; Congenital rubella syndrome (CRS) refers to variable constellations of birth defects (eg, hearing impairment, congenital heart defects,",
"      <span class=\"nowrap\">",
"       cataracts/congenital",
"      </span>",
"      glaucoma, pigmentary retinopathy, etc.) (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"mobipreview.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of intrauterine rubella infection is not altered by treatment with antiviral or biologic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], nor do these agents appear to have any long-term effect on the duration of viral shedding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care and surveillance and are the cornerstones of management for congenital rubella syndrome (CRS). Specific treatment depends upon the clinical manifestations, which may develop or progress over time (",
"    <a class=\"graphic graphic_table graphicRef75721 \" href=\"mobipreview.htm?15/35/15933\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the time of diagnosis, a comprehensive evaluation should be performed to determine the extent of disease severity. The evaluation should include thorough neurologic, cardiac, ophthalmologic, and audiologic examination; complete blood count; long-bone radiographs; and usually examination of cerebrospinal fluid (regardless of symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute management involves provision of supportive care and treatment of the clinical manifestations as necessary. Long-term management involves continued support and interventions for complications (eg, sensorineural hearing loss, cataracts, cardiac defects), and monitoring for progression or late manifestations (eg, hearing loss, endocrine problems). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Symptomatic management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Long-term monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neonatal period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most neonates with congenital rubella syndrome (CRS) have multiple problems and warrant multidisciplinary treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/5\">",
"     5",
"    </a>",
"    ]. They may require medical, surgical, developmental, and rehabilitative interventions.",
"   </p>",
"   <p>",
"    Most of the manifestations of CRS in the newborn period are nonspecific. They are managed in the same manner as they are in neonates without congenital rubella.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss &mdash; Hearing loss may require hearing aids and referral to an early intervention program. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link\">",
"       \"Screening the newborn for hearing loss\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"       \"Treatment of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Purpura and petechiae &mdash; Although purpura and petechiae may be severe, clinically significant bleeding is uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=see_link&amp;anchor=H23#H23\">",
"       \"Neonatal thrombocytopenia\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corneal clouding &mdash; Corneal clouding is suggestive of infantile glaucoma, which requires prompt referral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory distress &mdash; Neonates with respiratory distress should be managed with ventilatory support as necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperbilirubinemia &mdash; Hyperbilirubinemia (usually conjugated) is rarely severe. It should be managed in the same manner as it is in newborns without suspected congenital rubella infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=see_link\">",
"       \"Approach to neonatal cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatosplenomegaly &mdash; The hepatosplenomegaly in CRS usually does not require treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac disease &mdash; The cardiac evaluation for a child with suspected congenital rubella syndrome is the same as for infants without congenital rubella; cardiac failure should be treated vigorously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningoencephalitis &mdash; Provision of empiric antimicrobial therapy until culture of cerebrospinal fluid results are available and supportive care are the cornerstones of therapy for meningoencephalitis in neonates. Initial supportive care measures may include stabilization of cardiorespiratory status and treatment of seizures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"       \"Treatment of neonatal seizures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Older infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of congenital rubella syndrome (CRS) may develop over time. Hearing loss usually has onset during the first several years of life, but other manifestations may manifest later in childhood, adolescence, or adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/7-12\">",
"     7-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the manifestations in the newborn period, late-onset manifestations are nonspecific. These problems are treated in the same manner as they are for children who do not have congenital rubella syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss &mdash; Hearing loss may require hearing aids and referral to an early-intervention program. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"       \"Treatment of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Structural cardiac defects &mdash; Structural cardiac defects should be managed by a pediatric cardiologist. The management depends upon the defect:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patent ductus arteriosus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=see_link\">",
"       \"Management of patent ductus arteriosus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary artery stenosis",
"     </li>",
"     <li>",
"      Pulmonary valvular stenosis",
"     </li>",
"     <li>",
"      Aortic valve stenosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link\">",
"       \"Valvar aortic stenosis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular septal defect (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34680?source=see_link\">",
"       \"Management of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tetralogy of Fallot (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=see_link\">",
"       \"Overview of the management of tetralogy of Fallot\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coarctation of the aorta (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20922?source=see_link\">",
"       \"Management of coarctation of the aorta\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye disease &mdash; Cataracts, retinopathy, and infantile glaucoma require specialized management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"       \"Cataract in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central nervous system manifestations &mdash; Central nervous system manifestations (eg, intellectual disability) may require special education services and speech, language, occupational,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=see_link\">",
"       \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endocrine abnormalities &mdash; The late-onset endocrinologic abnormalities (eg, diabetes, thyroid dysfunction) should be managed by an endocrinologist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"       \"Management of type 1 diabetes mellitus in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25400?source=see_link\">",
"       \"Treatment and prognosis of Graves' disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link\">",
"       \"Acquired hypothyroidism in childhood and adolescence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LONG-TERM MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with congenital rubella syndrome require close monitoring during the first 6 to 12 months of life, particularly for hearing impairment and developmental abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These are among the most frequent late manifestations and often occur in infants who were asymptomatic at birth. Repeat testing over time is necessary to detect new or progressive manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing impairment is the most common manifestation of congenital rubella syndrome, and prompt diagnosis and institution of early intervention and educational programs are among the most important aspects of management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants exposed to rubella virus in utero should undergo objective hearing assessment during the neonatal period, at least once between 24 and 30 months of age (preferably more frequently), and then according to the American Academy of Pediatrics periodicity schedule (whether or not the infant has other manifestations of congenital rubella syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening tests in children and adolescents\", section on 'Hearing screen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hearing loss is detected, the child should be referred for early intervention services and fitted with an appropriate amplification device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Eye disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with congenital rubella syndrome (CRS) should undergo ophthalmologic evaluation. Ophthalmologic problems (ie, cataracts, glaucoma, strabismus) are managed in the same manner as they are in children without CRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. Retinopathy rarely causes significant visual deficit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of glaucoma in infants and children\", section on 'Secondary glaucoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term monitoring of congenital cardiac defects depends upon the defect:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patent ductus arteriosus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=see_link\">",
"       \"Management of patent ductus arteriosus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary artery stenosis",
"     </li>",
"     <li>",
"      Pulmonary valvular stenosis",
"     </li>",
"     <li>",
"      Aortic valve stenosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link\">",
"       \"Valvar aortic stenosis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular septal defect (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34680?source=see_link\">",
"       \"Management of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tetralogy of Fallot (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=see_link\">",
"       \"Overview of the management of tetralogy of Fallot\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coarctation of the aorta (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20922?source=see_link\">",
"       \"Management of coarctation of the aorta\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with congenital rubella syndrome are at increased risk for developmental problems. Developmental surveillance and screening are essential components of long-term care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endocrine disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to monitor children with congenital rubella syndrome for the development of diabetes and thyroid disease. Patients and caregivers should be educated about the signs and symptoms of these conditions. Healthcare providers should ask about symptoms and signs at health maintenance visits. Patients with clinical manifestations should undergo appropriate testing. Antithyroid antibodies may be measured as surrogate markers of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immune deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients with congenital rubella syndrome have low levels of serum immunoglobulin G (IgG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. Serum immunoglobulins should be measured when clinically indicated (eg, in children with recurrent infections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of mortality is increased in neonates with severe defects (eg, extreme prematurity, extensive meningoencephalitis, gross cardiac lesions or myocarditis with early heart failure, fulminant interstitial pneumonitis, and rapidly progressive hepatitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/15\">",
"     15",
"    </a>",
"    ]. In the original case series, the mortality rate among symptomatic infants was approximately 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up (at 25, 50, and 60 years) of a cohort of 50 patients born during the 1939-1943 rubella epidemic in Australia provides the following information about long-term outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 25 years, 48 of 50 patients were deaf; 43 of the 48 had severe bilateral deafness; hearing impairment was detected in all patients by seven years of age, in most patients by three years of age, but in only five patients by one year of age.",
"     </li>",
"     <li>",
"      At 25 years, 11 patients had congenital cardiovascular defects (patent ductus arteriosus, pulmonary stenosis, elevated systemic blood pressure); only two of these were detected in the first year of life; at 60 years, 21 of 32 patients had mild aortic valve sclerosis on echocardiography, and 12 were being treated for hypertension.",
"     </li>",
"     <li>",
"      At 25 years, 26 of 50 patients had typical rubella cataracts or chorioretinopathy; at 60 years, virtually all 32 patients had ocular conditions: rubella retinopathy (12), glaucoma (8), cataracts with onset between the 50- and 60-year follow-up (3), blindness (1), other ocular conditions (8).",
"     </li>",
"     <li>",
"      At 25 years, 50 percent of patients were below the 10th percentile for weight",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      height; at 50 years, 6 of 40 patients (15 percent) were below the 3rd percentile for height.",
"     </li>",
"     <li>",
"      At 50 years, 5 of 40 patients (12.5 percent) were diabetic; at 60 years, the prevalence of type 2 diabetes (22 percent), thyroid disorders (19 percent), early menopause (73 percent), and osteoporosis (12.5 percent) was increased compared with the Australian population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the most important aspect of management of congenital rubella infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls should be vaccinated against rubella before entering the childbearing years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=see_link&amp;anchor=H12#H12\">",
"     \"Rubella\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H22#H22\">",
"     \"Standard immunizations for children and adolescents\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women should be tested for rubella immunity. If they are not immune, they should be counseled regarding avoidance of exposure to patients with rubella and receive postpartum rubella immunization. Rubella vaccine should not be given to pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of pregnant women with rubella infection, the risk of transmission to the fetus, the likelihood of clinical manifestations, and the clinical manifestations of congenital rubella infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevention of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella virus is spread from person to person via airborne transmission or droplets shed from respiratory secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/18\">",
"     18",
"    </a>",
"    ]. It may be transmitted by persons with subclinical or asymptomatic infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Child care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CRS are considered to be contagious until at least one year of age unless they have consecutive nasopharyngeal and urine cultures that are negative for rubella virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Children with CRS who remain contagious should be cared for only by individuals who are immune to rubella (ie, have received at least one dose of rubella-containing vaccine on or after the first birthday or have a positive serologic test for rubella-specific IgG antibody) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with CRS remain actively infected and contagious at the time of birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. Droplet precautions should be instituted for hospitalized patients as soon as rubella or congenital rubella infection is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/5\">",
"     5",
"    </a>",
"    ]. Only individuals known to be rubella immune should care for contagious or potentially contagious patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of infection control\", section on 'Isolation precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No special precautions are necessary in the household setting for infants with CRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36855/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the family should be advised about the potential risks to pregnant visitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital rubella infection (CRI) refers to all outcomes associated with intrauterine rubella infection, including asymptomatic infection. Congenital rubella syndrome (CRS) refers to variable constellations of birth defects (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"mobipreview.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of intrauterine rubella infection is not altered by treatment with antiviral or biologic agents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care and surveillance are the cornerstones of management for congenital rubella infection. Specific treatment depends upon the clinical manifestations, which may develop or progress over time (",
"      <a class=\"graphic graphic_table graphicRef75721 \" href=\"mobipreview.htm?15/35/15933\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of congenital rubella syndrome are nonspecific (eg, hearing loss, meningoencephalitis, hepatosplenomegaly, thrombocytopenia, etc.). They are managed in the same manner as they are in neonates, infants, and children without congenital rubella syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptomatic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with congenital rubella syndrome require close monitoring during the first 6 to 12 months of life, particularly for hearing impairment and developmental abnormalities. Other late manifestations that should be monitored over time include eye disease (cataracts, glaucoma), endocrine disease, and immune deficiency. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Long-term monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention is the most important aspect of management of congenital rubella infection. Preventive measures include immunization of girls before they reach child-bearing age; testing pregnant women for rubella immunity and providing counseling regarding avoidance of exposure to rubella for those who are nonimmune; and ensuring that caregivers of children with congenital rubella syndrome in child care and hospital settings are rubella immune. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/1\">",
"      Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/2\">",
"      Plotkin SA, Klaus RM, Whitely JP. Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantanamine to stop irus excretion. J Pediatr 1966; 69:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/3\">",
"      Arvin AM, Schmidt NJ, Cantell K, Merigan TC. Alpha interferon administration to infants with congenital rubella. Antimicrob Agents Chemother 1982; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/4\">",
"      Larsson A, Forsgren M, H&aring;rd af Segerstad S, et al. Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis. Acta Paediatr Scand 1976; 65:105.",
"     </a>",
"    </li>",
"    <li>",
"     Plotkin, SA, Reef, SE, Cooper, LZ, Alford, CA. Rubella. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.861.",
"    </li>",
"    <li>",
"     Cherry JD. Rubella virus. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/7\">",
"      Menser MA, Dods L, Harley JD. A twenty-five-year follow-up of congenital rubella. Lancet 1967; 2:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/8\">",
"      McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992; 340:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/9\">",
"      Forrest JM, Turnbull FM, Sholler GF, et al. Gregg's congenital rubella patients 60 years later. Med J Aust 2002; 177:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/10\">",
"      Alford CA Jr, Kanich LS. Congenital rubella: a review of the virologic and serologic phenomena occurring after maternal rubella in the first trimester. South Med J 1966; 59:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/11\">",
"      Cradock-Watson JE, Ridehalgh MK, Anderson MJ, et al. Fetal infection resulting from maternal rubella after the first trimester of pregnancy. J Hyg (Lond) 1980; 85:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/12\">",
"      Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch Dis Child 1972; 47:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/13\">",
"      American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/14\">",
"      Harlor AD Jr, Bower C, Committee on Practice and Ambulatory Medicine, Section on Otolaryngology-Head and Neck Surgery. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics 2009; 124:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/15\">",
"      Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis 1985; 7 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/16\">",
"      Gregg, N. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/17\">",
"      GREGG NM. Congenital defects associated with maternal rubella. Aust Hosp 1947; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/19\">",
"      Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Rubella. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36855/abstract/21\">",
"      Rubella prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep1990; 39(RR-15):1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6039 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36855=[""].join("\n");
var outline_f35_63_36855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYMPTOMATIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neonatal period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Older infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LONG-TERM MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Eye disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endocrine disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevention of transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Child care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39820\" title=\"table 1\">",
"      CRS case definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/35/15933\" title=\"table 2\">",
"      Congenital rubella ssx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/55/34680?source=related_link\">",
"      Management of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33448?source=related_link\">",
"      Management of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25400?source=related_link\">",
"      Treatment and prognosis of Graves' disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36856="Third cranial nerve (oculomotor nerve) palsy in adults";
var content_f35_63_36856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Third cranial nerve (oculomotor nerve) palsy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36856/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/63/36856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the third cranial nerve (oculomotor nerve) can result from lesions anywhere along its path between the oculomotor nucleus in the midbrain and the extraocular muscles within the orbit. The diagnosis and management of third nerve palsy varies according to the age of the patient, characteristics of the third nerve palsy, and the presence of associated signs and symptoms.",
"   </p>",
"   <p>",
"    The manifestations and diagnosis of third nerve palsy in adults will be reviewed here. Third nerve palsy in children and other causes of diplopia, ptosis, and anisocoria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25320?source=see_link\">",
"     \"Overview of diplopia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31255?source=see_link\">",
"     \"Overview of ptosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=see_link\">",
"     \"Approach to the patient with anisocoria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third cranial nerve supplies the levator muscle of the eyelid and four extraocular muscles: the medial rectus, superior rectus, inferior rectus, and inferior oblique. These muscles adduct, depress, and elevate the eye. The superior oblique muscle is innervated by cranial nerve IV and the lateral rectus muscle by cranial nerve VI. In addition, the third cranial nerve constricts the pupil through its parasympathetic fibers that supply the smooth muscle of the ciliary body and the sphincter of the iris.",
"   </p>",
"   <p>",
"    The third nerve begins as a nucleus in the midbrain that consists of several subnuclei that innervate the individual extraocular muscles, the eyelids, and the pupils. Each subnucleus, except the superior rectus subnucleus, supplies the ipsilateral muscle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior rectus subnucleus innervates the contralateral superior rectus muscle",
"     </li>",
"     <li>",
"      The levator subnucleus is a single central caudate nucleus and innervates both levator palpebrae superioris muscles (which control the eyelids)",
"     </li>",
"     <li>",
"      The parasympathetic pupil nucleus (Edinger-Westphal nuclei) controls pupil constriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The third nerve fascicle leaves the nucleus and passes ventrally near important structures in the midbrain (eg, red nucleus, corticospinal tract). The third nerve then enters the subarachnoid space, passes into the lateral wall of the cavernous sinus, and finally divides into superior and inferior branches as it enters the superior orbital fissure in the orbit to innervate the extraocular muscles (",
"    <a class=\"graphic graphic_figure graphicRef76281 \" href=\"mobipreview.htm?6/60/7110\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The superior division of the third nerve supplies the levator palpebrae and the superior rectus, while the inferior division supplies the medial and inferior rectus muscles, the inferior oblique, and the pupillary sphincter. Because the fibers are topographically organized within the third nerve fascicle and nerve, a pattern of deficits that represents a divisional palsy is not helpful in anatomic localization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an acute acquired third nerve palsy usually complain of the sudden onset of binocular horizontal, vertical, or oblique diplopia and a droopy eyelid. Infrequently, the patient is aware of an enlarged pupil. Patients with chronic third nerve palsies (especially with primary aberrant regeneration) may be asymptomatic. Pain accompanying the onset of third nerve palsy is common, except in midbrain lesions, and is not useful to distinguish among etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/2\">",
"     2",
"    </a>",
"    ]. Sudden, severe pain (\"the worst headache of my life\") might suggest subarachnoid hemorrhage due to a ruptured aneurysm as the cause of the third nerve palsy. Severe pain may also be present in inflammatory lesions or pituitary apoplexy, but mild or moderate pain is also common in ischemic lesions.",
"   </p>",
"   <p>",
"    On examination, patients with a complete nonpupil-sparing third nerve palsy have ptosis, a large unreactive pupil, and paralysis of adduction, elevation, and depression. The eye rests in a position of abduction, slight depression, and intorsion \"down and out\" (",
"    <a class=\"graphic graphic_picture graphicRef77466 \" href=\"mobipreview.htm?37/3/37936\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In partial lesions, the pupil may be of normal size and normally reactive (no internal dysfunction), dilated and poorly reactive (partial internal dysfunction), or dilated and non-reactive to light and near stimulus (complete internal dysfunction). The asymmetry of pupil size is greater in the light than in the dark. There may be complete or incomplete involvement of the extraocular muscles (external dysfunction) innervated by the third nerve, producing varying degrees of ptosis as well as weakness of ipsilateral adduction (medial rectus), elevation (superior rectus, inferior oblique),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression (inferior rectus). A partial third nerve palsy with a normal pupil, ptosis, and restricted upgaze is shown (",
"    <a class=\"graphic graphic_picture graphicRef69413 \" href=\"mobipreview.htm?20/59/21431\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The remainder of the clinical presentation varies depending upon the location and type of lesion (",
"    <a class=\"graphic graphic_table graphicRef56375 \" href=\"mobipreview.htm?30/4/30796\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purposes of clinical evaluation, we classify third nerve palsies as neurologically isolated or neurologically non-isolated according to the presence of other neurologic deficits or systemic symptoms. We further characterize neurologically isolated lesions as having normal internal function (pupil-sparing) or abnormal internal function (nonpupil-sparing). Complete external dysfunction is identified when there is impairment of the majority of function of all the somatic branches of the oculomotor nerve and ptosis is complete or almost complete; otherwise the external dysfunction is incomplete (eg, divisional palsy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Midbrain lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the third nerve nucleus are rare and are usually associated with other neurologic deficits localized to the midbrain. The most characteristic finding of a nuclear lesion is a complete unilateral third nerve palsy with weakness of both the ipsilateral and contralateral superior rectus (because the superior rectus subnucleus is crossed) and bilateral, incomplete ptosis. The levator palpebrae superioris muscles are controlled by a single central subnucleus. Thus, in patients with nuclear lesions, if ptosis is present, it is bilateral.",
"   </p>",
"   <p>",
"    Other patterns of third nerve deficits can be seen occur in nuclear lesions, including bilateral third nerve palsies with sparing of the eyelids and isolated bilateral ptosis with sparing of the extraocular muscles and pupils. Nuclear third nerve palsies can occasionally be associated with ipsilateral ptosis and contralateral eyelid retraction (plus-minus lid syndrome) if supranuclear inhibitory input to the third nerve is disrupted and ptosis from a fascicular lesion on the contralateral side occurs.",
"   </p>",
"   <p>",
"    Nuclear lesions can also cause isolated extraocular muscle involvement. However, unilateral or bilateral isolated medial rectus paralysis is unlikely to be caused by a nuclear lesion because medial rectus neurons probably lie at three different locations within the oculomotor nucleus. For this reason, patients with presumed isolated medial rectus paresis should be evaluated for internuclear ophthalmoplegia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=see_link\">",
"     \"Internuclear ophthalmoplegia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nuclear lesions that are caused by infarction are often accompanied by lesions of the third nerve fascicle because both structures are supplied by the paramedian branches of the basilar artery.",
"   </p>",
"   <p>",
"    A nuclear or fascicular third nerve lesion almost always occurs with other neurologic signs or symptoms, which identifies the midbrain location of the lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contralateral ataxia will be present if the red",
"      <span class=\"nowrap\">",
"       nucleus/superior",
"      </span>",
"      cerebellar peduncle is involved",
"     </li>",
"     <li>",
"      Cerebellar tremor may be present in Claude syndrome (ipsilateral third nerve palsy and contralateral cerebellar signs)",
"     </li>",
"     <li>",
"      Contralateral hemiparesis may be present in a cerebral peduncle lesion (Weber syndrome)",
"     </li>",
"     <li>",
"      Contralateral choreiform movements or tremor are present when red",
"      <span class=\"nowrap\">",
"       nucleus/substantia",
"      </span>",
"      nigra involvement occurs (Benedikt syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Subarachnoid space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated third nerve palsies often localize to a lesion within the subarachnoid space. In adults, extra-axial third nerve palsies usually are caused by ischemia. In contrast, ischemia is a rare cause for third nerve palsy in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    .) In addition to ischemia, other causes include aneurysmal compression, infection, inflammation, neoplasia, uncal herniation, and trauma (including neurosurgical procedures) (",
"    <a class=\"graphic graphic_table graphicRef56375 \" href=\"mobipreview.htm?30/4/30796\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical features of lesions in this area are to some extent specific to etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory, infectious, and neoplastic disorders affecting the meninges will often produce other cranial nerve deficits along with a third nerve palsy; otherwise these lesions are typically neurologically isolated.",
"     </li>",
"     <li>",
"      Ischemic third nerve lesions typically present with intact pupillary function (80 to 90 percent of cases), probably because of the lack of damage to the superficial periphery of the third nerve where the majority of pupillomotor fibers are thought to pass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/4-11\">",
"       4-11",
"      </a>",
"      ]. When the pupil is involved, impairment is usually incomplete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/5,12\">",
"       5,12",
"      </a>",
"      ]. In one series of 26 patients with ischemic third nerve palsy, most patients with impaired pupillary function had only mild anisocoria (&lt;1 mm) and none had a fully dilated pupil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, aneurysmal compression of the superficial pupil fibers of the third nerve in the subarachnoid space usually results in a dilated and unresponsive pupil. However, aneurysms can rarely present without pupil involvement, especially if there is incomplete external dysfunction (eg, divisional palsy). When there is incomplete external dysfunction, the lack of pupil involvement does not have the same diagnostic significance as true pupil-sparing in the setting of a third nerve palsy with complete external dysfunction.",
"     </li>",
"     <li>",
"      Signs of aberrant regeneration or oculomotor synkinesis are common with lesions caused by nerve compression or after trauma and are rare with ischemic lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/13\">",
"       13",
"      </a>",
"      ]. These signs include lid retraction with adduction or down-gaze, globe retraction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adduction with attempted vertical gaze, and pupil constriction with eye movement using third nerve-innervated muscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spontaneous improvement of symptoms should not be reassuring in regards to diagnosis; this has been described with aneurysmal lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cavernous sinus lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the third nerve in the cavernous sinus and superior orbital fissure often involve other cranial nerves and have the following clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fourth cranial nerve - vertical diplopia (look for lack of intorsion in downgaze in a patient with complete third nerve palsy and possible fourth nerve deficit)",
"     </li>",
"     <li>",
"      Sixth cranial nerve - horizontal diplopia; esotropia (inward deviation)",
"     </li>",
"     <li>",
"      First (ophthalmic) branch of the trigeminal nerve - pain or numbness",
"     </li>",
"     <li>",
"      Oculosympathetic fibers - Horner's syndrome (look for a smaller pupil on the side of the third nerve palsy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Superior orbital fissure/Orbital lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions within the orbit that produce third-nerve dysfunction usually produce other orbital signs, including optic neuropathy, chemosis, conjunctival injection or chemosis, and proptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Etiologies of third nerve palsies are specific to the location (",
"    <a class=\"graphic graphic_table graphicRef56375 \" href=\"mobipreview.htm?30/4/30796\">",
"     table 1",
"    </a>",
"    ). These include a wide variety of pathologies, including structural lesions, cerebrovascular disease, inflammatory or infectious conditions, and trauma. In this regard, a few deserve specific comment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial aneurysm &mdash; The most dreaded cause of a third nerve palsy is compression by an enlarging intracranial aneurysm. The most common site of an aneurysm causing a third nerve palsy is the posterior communicating artery; however, aneurysms involving the internal carotid artery and basilar artery are reported to produce third nerve palsies as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]. In the setting of an acute third nerve palsy, the aneurysm is believed to be acutely enlarging and therefore at risk of imminent rupture. In this setting, subarachnoid hemorrhage can occur within hours or days of initial presentation of the third nerve palsy. The mean age of presentation of aneurysmal subarachnoid hemorrhage is 55 years; however, aneurysms have been reported in young children and in the elderly.",
"     </li>",
"     <li>",
"      Ischemia &mdash; Ischemic third nerve palsies, also called diabetic third nerve palsies, are the most common etiologic subset of third nerve palsy in adults. The pathogenesis is felt to be microvascular; hypertension and advanced age are also risk factors. While some isolated ischemic third nerve palsies are due to midbrain infarction, most are peripheral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trauma &mdash; Traumatic third nerve palsy usually arises only from severe blows to the head, with skull fracture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of consciousness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14,22,23\">",
"       14,22,23",
"      </a>",
"      ]. Thus, a third nerve palsy associated with mild head trauma should prompt evaluation for associated pathology.",
"     </li>",
"     <li>",
"      Migraine &mdash; Ophthalmoplegic 'migraine,' a condition affecting children and young adults, was reclassified as a cranial neuralgia in the revised International Headache Society (IHS) headache classification system published in 2004 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/24\">",
"       24",
"      </a>",
"      ]. This most commonly affects the third cranial nerve, sometimes with permanent deficits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/25\">",
"       25",
"      </a>",
"      ]. Several cases have been reported in which ophthalmoplegic 'migraine' is associated with MRI (magnetic resonance imaging) gadolinium enhancement of the cisternal segment of the affected cranial nerve in patients with a typical clinical presentation, suggesting that the condition may be a recurrent demyelinating neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/26-29\">",
"       26-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions can mimic the extraocular dysfunction of third nerve palsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While often considered, third nerve palsy is extremely unlikely to be the cause of isolated mydriasis. Tonic pupil, iris sphincter damage, and pharmacologic mydriasis should be specifically excluded by careful neuroophthalmologic evaluation and pharmacologic testing in this setting. A complete evaluation of the lid and the ocular motility should also be performed to insure that the anisocoria is an isolated finding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=see_link\">",
"       \"Approach to the patient with anisocoria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orbital disease, eg, orbital fracture, tumor, and inflammation, can affect the extraocular muscles directly. Forced ductions, passive rotation of the eyes with ophthalmic forceps, might confirm the restrictive nature of the ophthalmoplegia caused by these problems.",
"     </li>",
"     <li>",
"      Myasthenia gravis can mimic any painless, pupil-sparing ophthalmoplegia and should be considered in every patient with a pupil-sparing third nerve palsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/30\">",
"       30",
"      </a>",
"      ]. Other signs of myasthenia gravis, such as ptosis, variability, and fatigue, usually are present. The \"ice test\" (a two-minute application of ice to the eyelid with ptosis) may help to differentiate myasthenia from other causes of ptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. A positive test (&ge;2 mm improvement in ptosis) was 80 percent sensitive and 100 percent specific in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=see_link\">",
"       \"Ocular myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skew deviation is a vertical misalignment caused by disruption of the vestibuloocular connections and can result in hypertropia. Usually it is associated with other posterior fossa signs (eg, other cranial neuropathies, hemisensory loss, or hemiparesis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25320?source=see_link\">",
"       \"Overview of diplopia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient with a third nerve palsy depends on associated symptoms and signs and the pattern of oculomotor nerve involvement, both of which help to localize the lesion anatomically (",
"    <a class=\"graphic graphic_table graphicRef56375 \" href=\"mobipreview.htm?30/4/30796\">",
"     table 1",
"    </a>",
"    ). The age of the patient and other historical features also help to distinguish congenital, traumatic, or infectious conditions. Inflammatory and neoplastic conditions have a more insidious onset compared with cerebral infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nonisolated third nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third nerve palsies that are accompanied by other neurologic deficits, orbital signs, or meningismus require an evaluation that usually includes neuroimaging. A lumbar puncture (LP) may also be required to evaluate for possible infectious, inflammatory, or carcinomatous meningitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A brain magnetic resonance imaging study (MRI) is indicated for patients with findings suggesting a lesion of the nerve's nuclear or fascicular course within the brainstem. These findings include bilateral ptosis, contralateral superior rectus palsy, hemiparesis, ataxia, and tremor. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Midbrain lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accompanying meningeal signs (eg, headache, stiff neck, and depressed level of consciousness) or other cranial nerve involvement, especially if bilateral, should prompt evaluation of the cerebrospinal fluid by LP for possible meningitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sudden onset of painful third nerve palsy with associated meningeal signs demands an emergent evaluation, regardless of the patient's age or the extent of third nerve involvement, including those that spare pupillary function. The emergent work-up should include head computed tomography (CT) without contrast looking for blood in the subarachnoid space. If the head CT is unrevealing, LP should be performed to exclude subarachnoid hemorrhage. In the absence of subarachnoid hemorrhage, testing should be performed to exclude an unruptured intracranial aneurysm. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Isolated third nerve palsy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Signs that localize to the cavernous sinus or orbital apex indicate a brain MRI with gadolinium&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cavernous sinus lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Superior orbital fissure/Orbital lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Isolated third nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to the patient with an isolated third nerve palsy differs among clinicians, and some issues remain controversial. Considerations include the extent of internal and external third nerve dysfunction, the age of the patient, and medical comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119291787\">",
"    <span class=\"h3\">",
"     Evaluation for intracranial aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;On presentation, the first consideration is to assess the risk of an underlying intracranial aneurysm because of the potential risk of imminent subarachnoid hemorrhage. Imaging studies used to diagnose or exclude an intracranial aneurysm include contrast-enhanced MRI with MR angiography (MRA), computed tomographic angiography (CTA), and cerebral angiography. Cerebral angiography remains the gold standard test but is invasive and associated with infrequent but significant risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. The risk of the catheter angiography must therefore be weighed against the risk of missing an aneurysm in the individual patient. Factors to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrast-enhanced MRI with MRA or CTA have a sensitivity as high as 95 to 98 percent for the detection of aneurysm in the setting of a third nerve palsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. The quality and reliability of each of these studies and their interpretation are to some extent institution-specific and should be ordered in consultation with the interpreting neuroradiologist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/38\">",
"       38",
"      </a>",
"      ]. While some centers prefer CTA as a first study to exclude aneurysm, MRI is superior for nonaneurysmal etiologies of a third nerve palsy. A combination of CTA and MRI (with or without MRA) might be necessary in this regard. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link&amp;anchor=H21#H21\">",
"       \"Unruptured intracranial aneurysms\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of standard catheter angiography also depends on institution-specific factors as well as on and patient age and medical comorbidity.",
"     </li>",
"     <li>",
"      The relative risk of an underlying aneurysm is assessed based in large part on the degree of external and internal third nerve dysfunction as discussed in the following sections, (",
"      <a class=\"graphic graphic_table graphicRef76645 \" href=\"mobipreview.htm?13/17/13596\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When indicated, testing to exclude intracranial aneurysm should proceed emergently, as the risk of aneurysm rupture may be imminent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119291508\">",
"    <span class=\"h3\">",
"     Complete external dysfunction with normal internal function (pupil-sparing complete third nerve palsy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neurologically isolated third nerve palsy with a normal pupillary sphincter and completely palsied extraocular muscles (complete external dysfunction) is almost never caused by an aneurysm. A single case has been reported due to a basilar artery aneurysm, but this is exceptional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older adults, this presentation is most commonly caused by ischemic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/12,39\">",
"     12,39",
"    </a>",
"    ]. Observation alone is an appropriate diagnostic option for older patients with vascular risk factors (hypertension, diabetes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/39\">",
"     39",
"    </a>",
"    ]. However, contrast-enhanced brain MRI and MRA should be strongly considered in patients without vascular risk factors whose deficits progress or do not improve by 6 to 12 weeks of follow-up or in those with signs of aberrant regeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/13\">",
"     13",
"    </a>",
"    ]. In some hospitals, combined examination with CT and CTA may be superior to MRA for aneurysm evaluation. However, MRI is superior to CT for imaging the cavernous sinus, posterior fossa, and meninges and is the preferred imaging study for third nerve palsy.",
"   </p>",
"   <p>",
"    Older patients (&gt;55 years) should be evaluated for signs or symptoms of giant cell arteritis (headache, jaw or tongue claudication, polymyalgia rheumatica, visual loss) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. These patients may require serum erythrocyte sedimentation rate and C reactive protein, steroid treatment, and temporal artery biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a third nerve palsy persists in a patient with normal imaging studies, a lumbar puncture (LP) should be considered, especially if historical or examination features suggest an infectious, inflammatory, or neoplastic process affecting the meninges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119291515\">",
"    <span class=\"h3\">",
"     Third nerve palsy with complete internal dysfunction (pupil-involved) and complete or incomplete external dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete internal dysfunction (pupil-involved) third nerve palsy should be assumed to be due to aneurysmal compression until proven otherwise. Patients should undergo MRI and MRA (or CTA); however, even if the noninvasive study is negative, a catheter angiogram should be strongly considered to exclude aneurysm.",
"   </p>",
"   <p>",
"    Once aneurysm and other mass lesions have been excluded, an evaluation for giant cell arteritis should be undertaken in older patients; and an LP should be considered for persistent or progressing deficits when the cause remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119291523\">",
"    <span class=\"h3\">",
"     Other patterns of isolated third nerve deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other patterns of isolated third nerve deficits include incomplete external dysfunction with no pupil involvement (eg, divisional palsy) and incomplete or complete external dysfunction with partial internal dysfunction (relative pupil-sparing). These patients should undergo a contrast-enhanced brain MRI to exclude a mass lesion, with an MRA or CTA to look for an aneurysm or other mass lesion. If negative, catheter angiography should be considered to further investigate the presence of an aneurysm or the less likely possibility of a posterior draining carotid-cavernous sinus fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/2\">",
"     2",
"    </a>",
"    ]. In this intermediate risk category, individual and institution-specific assessments of risks and benefits determine the choice of testing.",
"   </p>",
"   <p>",
"    As discussed above, an evaluation for giant cell arteritis should be undertaken in older patients, and an LP should be considered for persistent or progressing deficits when the cause remains unclear after neuroimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119291530\">",
"    <span class=\"h3\">",
"     Isolated third nerve palsy with signs of aberrant regeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of aberrant regeneration are unlikely in ischemic lesions and suggest the presence of a compressive lesion, including aneurysm (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Subarachnoid space'",
"    </a>",
"    above). Contrast-enhanced brain MRI with MRA (or CTA) is the procedure of choice for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is directed at the underlying etiology of the third nerve palsy.",
"   </p>",
"   <p>",
"    In most cases, third nerve deficits, diplopia, and ptosis recover over weeks to months. Deficits that are present at six months are usually persistent over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intervention for an aneurysmal third nerve palsy is primarily directed at preventing subarachnoid hemorrhage. Recovery of third nerve function occurs in most who undergo either neurosurgical clipping or endovascular embolization, but may be incomplete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/3,14,37,42-53\">",
"     3,14,37,42-53",
"    </a>",
"    ]. The time course of recovery varies from a few weeks to several months, and may be influenced by the degree",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duration of deficit preoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/42,54\">",
"     42,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link&amp;anchor=H22#H22\">",
"     \"Unruptured intracranial aneurysms\", section on 'Management of unruptured aneurysms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of ischemic third nerve palsies, including those related to migraine headaches, usually improve over three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"     14",
"    </a>",
"    ]. Vascular risk factors should be treated; antiplatelet therapy is usually provided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have traumatic third nerve palsies, particularly those who have partial palsies, may experience spontaneous resolution, but the prognosis is not as favorable as with ischemic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Persistent deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patching one eye is useful in alleviating diplopia, particularly in the short term.",
"   </p>",
"   <p>",
"    Prism therapy may be employed for small, comitant, long-standing deviations. \"Comitant\" deviations are those in which the distance between the double images is little affected by the direction of gaze. A temporary press-on (Fresnel) prism of sufficient power to align the eyes is placed on the spectacle lens of the affected child. Permanent prisms can be ground into the spectacle lens if the patient has a stable but symptomatic deviation alleviated with prism.",
"   </p>",
"   <p>",
"    Strabismus surgery may be helpful in patients who fail prism therapy. However, this surgery is difficult to perform, particularly in those with complete third nerve palsies, because multiple muscles are involved; ocular alignment in primary position might be achievable but might require multiple procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36856/abstract/49,55\">",
"     49,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ptosis surgery may be necessary in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31255?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of ptosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A third cranial nerve palsy can result from lesions anywhere along its path between the oculomotor nucleus in the midbrain and the extraocular muscles within the orbit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficits resulting from a third nerve palsy with complete external dysfunction include ptosis and paralysis of adduction, elevation, and depression. Complete internal (pupil sphincter) dysfunction is manifested by a large, unreactive pupil. Partial internal dysfunction can produce anisocoria with a sluggish but reactive pupil. Third nerve palsies are classified as being neurologically isolated or neurologically nonisolated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Associated clinical features, particularly other neurologic deficits, can help localize the site of injury and identify possible etiologies (",
"      <a class=\"graphic graphic_table graphicRef56375 \" href=\"mobipreview.htm?30/4/30796\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most feared cause of an isolated acute third nerve palsy is an intracranial aneurysm because of its attendant risk of potentially fatal subarachnoid hemorrhage. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient with acute third nerve palsy and sudden headache",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningeal signs should have an emergent noncontrast head computed tomography (CT) to look for subarachnoid hemorrhage. Other testing should follow if suspicion for aneurysmal subarachnoid hemorrhage remains. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonisolated third nerve palsy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other patients with nonneurologically isolated third nerve palsy should undergo neuroimaging (contrast-enhanced magnetic resonance imaging (MRI) with MR angiography or CT angiography) and if that is negative, lumbar puncture or other laboratory testing. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonisolated third nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For isolated third nerve palsies, the degree of external and internal dysfunction can be used to determine the type and urgency of imaging, including the risk to benefit analysis for proceeding to catheter angiography (",
"      <a class=\"graphic graphic_table graphicRef76645 \" href=\"mobipreview.htm?13/17/13596\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Isolated third nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observation alone is appropriate only for isolated third nerve palsies with complete external dysfunction and normal internal function (pupil-sparing) in an older patient with vascular risk factors who improves and does not develop aberrant regeneration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Isolated third nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cranial contrast enhanced MRI with MR angiography, or cranial contrast enhanced CT angiography followed by",
"      <span class=\"nowrap\">",
"       MRI/MRA",
"      </span>",
"      are appropriate initial imaging strategies for other presentations of third nerve palsy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Isolated third nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter angiography might still be necessary in patients with a high pretest likelihood of aneurysm (eg, pupil-involved third nerve palsy) even in the setting of a negative MRI with MRA or CTA, depending on institution and patient-specific factors. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Isolated third nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, diplopia and ptosis recover over several weeks to months. Deficits present at six months are generally persistent. Such patients may benefit from surgical interventions to alleviate disabling diplopia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ptosis (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment and Prognosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/1\">",
"      Bhatti MT, Eisenschenk S, Roper SN, Guy JR. Superior divisional third cranial nerve paresis: clinical and anatomical observations of 2 unique cases. Arch Neurol 2006; 63:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/2\">",
"      Jacobson DM. Relative pupil-sparing third nerve palsy: etiology and clinical variables predictive of a mass. Neurology 2001; 56:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/3\">",
"      Brazis PW, Lee AG. Binocular vertical diplopia. Mayo Clin Proc 1998; 73:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/4\">",
"      Jacobson DM, McCanna TD, Layde PM. Risk factors for ischemic ocular motor nerve palsies. Arch Ophthalmol 1994; 112:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/5\">",
"      Jacobson DM. Pupil involvement in patients with diabetes-associated oculomotor nerve palsy. Arch Ophthalmol 1998; 116:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/6\">",
"      Nadeau SE, Trobe JD. Pupil sparing in oculomotor palsy: a brief review. Ann Neurol 1983; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/7\">",
"      Richards BW, Jones FR Jr, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol 1992; 113:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/8\">",
"      RUCKER CW. Paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1958; 46:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/9\">",
"      Rucker CW. The causes of paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1966; 61:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/10\">",
"      Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol 1981; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/11\">",
"      Teuscher AU, Meienberg O. Ischaemic oculomotor nerve palsy. Clinical features and vascular risk factors in 23 patients. J Neurol 1985; 232:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/12\">",
"      Chou KL, Galetta SL, Liu GT, et al. Acute ocular motor mononeuropathies: prospective study of the roles of neuroimaging and clinical assessment. J Neurol Sci 2004; 219:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/13\">",
"      Carrasco JR, Savino PJ, Bilyk JR. Primary aberrant oculomotor nerve regeneration from a posterior communicating artery aneurysm. Arch Ophthalmol 2002; 120:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/14\">",
"      Biousse V, Newman NJ. Third nerve palsies. Semin Neurol 2000; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/15\">",
"      Arle JE, Abrahams JM, Zager EL, et al. Pupil-sparing third nerve palsy with preoperative improvement from a posterior communicating artery aneurysm. Surg Neurol 2002; 57:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/16\">",
"      Foroozan R, Slamovits TL, Ksiazek SM, Zak R. Spontaneous resolution of aneurysmal third nerve palsy. J Neuroophthalmol 2002; 22:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/17\">",
"      Lustbader JM, Miller NR. Painless, pupil-sparing but otherwise complete oculomotor nerve paresis caused by basilar artery aneurysm. Case report. Arch Ophthalmol 1988; 106:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/18\">",
"      Levy J, Marcus M, Shelef I, Lifshitz T. Acute angle-closure glaucoma and pupil-involving complete third nerve palsy as presenting signs of thrombosed cavernous sinus aneurysm. Eye (Lond) 2004; 18:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/19\">",
"      Satyarthee GD, Mahapatra AK. Unusual neuro-ophthalmic presentation of anterior communicating artery aneurysm with third nerve paresis. J Clin Neurosci 2004; 11:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/20\">",
"      Ikeda K, Tamura M, Iwasaki Y, Kinoshita M. Relative pupil-sparing third nerve palsy: etiology and clinical variables predictive of a mass. Neurology 2001; 57:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/21\">",
"      Keane JR, Ahmadi J. Most diabetic third nerve palsies are peripheral. Neurology 1998; 51:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/22\">",
"      Eyster EF, Hoyt WF, Wilson CB. Oculomotor palsy from minor head trauma. An initial sign of basal intracranial tumor. JAMA 1972; 220:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/23\">",
"      Levy RL, Geist CE, Miller NR. Isolated oculomotor palsy following minor head trauma. Neurology 2005; 65:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/24\">",
"      Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/25\">",
"      Bartleson JD. Transient and persistent neurological manifestations of migraine. Stroke 1984; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/26\">",
"      Mark AS, Casselman J, Brown D, et al. Ophthalmoplegic migraine: reversible enhancement and thickening of the cisternal segment of the oculomotor nerve on contrast-enhanced MR images. AJNR Am J Neuroradiol 1998; 19:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/27\">",
"      Lance JW, Zagami AS. Ophthalmoplegic migraine: a recurrent demyelinating neuropathy? Cephalalgia 2001; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/28\">",
"      O'Hara MA, Anderson RT, Brown D. Magnetic resonance imaging in ophthalmoplegic migraine of children. J AAPOS 2001; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/29\">",
"      De Silva DA, Siow HC. A case report of ophthalmoplegic migraine: a differential diagnosis of third nerve palsy. Cephalalgia 2005; 25:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/30\">",
"      Kim JH, Hwang JM, Hwang YS, et al. Childhood ocular myasthenia gravis. Ophthalmology 2003; 110:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/31\">",
"      Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/32\">",
"      Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987; 37:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/33\">",
"      Ellis FD, Hoyt CS, Ellis FJ, et al. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS 2000; 4:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/34\">",
"      Jacobson DM, Trobe JD. The emerging role of magnetic resonance angiography in the management of patients with third cranial nerve palsy. Am J Ophthalmol 1999; 128:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/35\">",
"      Heiserman JE, Dean BL, Hodak JA, et al. Neurologic complications of cerebral angiography. AJNR Am J Neuroradiol 1994; 15:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/36\">",
"      Dion JE, Gates PC, Fox AJ, et al. Clinical events following neuroangiography: a prospective study. Stroke 1987; 18:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/37\">",
"      Bartleson JD, Trautmann JC, Sundt TM Jr. Minimal oculomotor nerve paresis secondary to unruptured intracranial aneurysm. Arch Neurol 1986; 43:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/38\">",
"      Elmalem VI, Hudgins PA, Bruce BB, et al. Underdiagnosis of posterior communicating artery aneurysm in noninvasive brain vascular studies. J Neuroophthalmol 2011; 31:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/39\">",
"      Lee SH, Lee SS, Park KY, Han SH. Isolated oculomotor nerve palsy: diagnostic approach using the degree of external and internal dysfunction. Clin Neurol Neurosurg 2002; 104:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/40\">",
"      Loffredo L, Parrotto S, Violi F. Giant cell arteritis, oculomotor nerve palsy, and acute hearing loss. Scand J Rheumatol 2004; 33:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/41\">",
"      Day A, Malik N. Giant cell arteritis presenting as painful third nerve palsy. Br J Hosp Med (Lond) 2006; 67:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/42\">",
"      Yanaka K, Matsumaru Y, Mashiko R, et al. Small unruptured cerebral aneurysms presenting with oculomotor nerve palsy. Neurosurgery 2003; 52:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/43\">",
"      White PM, Wardlaw JM, Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology 2000; 217:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/44\">",
"      Hashimoto H, Iida J, Hironaka Y, et al. Use of spiral computerized tomography angiography in patients with subarachnoid hemorrhage in whom subtraction angiography did not reveal cerebral aneurysms. J Neurosurg 2000; 92:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/45\">",
"      Korogi Y, Takahashi M, Katada K, et al. Intracranial aneurysms: detection with three-dimensional CT angiography with volume rendering--comparison with conventional angiographic and surgical findings. Radiology 1999; 211:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/46\">",
"      Zouaoui A, Sahel M, Marro B, et al. Three-dimensional computed tomographic angiography in detection of cerebral aneurysms in acute subarachnoid hemorrhage. Neurosurgery 1997; 41:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/47\">",
"      Lee AG, Onan HW, Brazis PW, Prager TC. An imaging guide to the evaluation of third cranial nerve palsies. Strabismus 1999; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/48\">",
"      Good WV, Barkovich AJ, Nickel BL, Hoyt CS. Bilateral congenital oculomotor nerve palsy in a child with brain anomalies. Am J Ophthalmol 1991; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/49\">",
"      Gottlob I, Catalano RA, Reinecke RD. Surgical management of oculomotor nerve palsy. Am J Ophthalmol 1991; 111:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/50\">",
"      Preechawat P, Sukawatcharin P, Poonyathalang A, Lekskul A. Aneurysmal third nerve palsy. J Med Assoc Thai 2004; 87:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/51\">",
"      Birchall D, Khangure MS, McAuliffe W. Resolution of third nerve paresis after endovascular management of aneurysms of the posterior communicating artery. AJNR Am J Neuroradiol 1999; 20:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/52\">",
"      Chen PR, Amin-Hanjani S, Albuquerque FC, et al. Outcome of oculomotor nerve palsy from posterior communicating artery aneurysms: comparison of clipping and coiling. Neurosurgery 2006; 58:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/53\">",
"      Inamasu J, Nakamura Y, Saito R, et al. Early resolution of third nerve palsy following endovascular treatment of a posterior communicating artery aneurysm. J Neuroophthalmol 2002; 22:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/54\">",
"      Dimopoulos VG, Fountas KN, Feltes CH, et al. Literature review regarding the methodology of assessing third nerve paresis associated with non-ruptured posterior communicating artery aneurysms. Neurosurg Rev 2005; 28:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36856/abstract/55\">",
"      Schumacher-Feero LA, Yoo KW, Solari FM, Biglan AW. Third cranial nerve palsy in children. Am J Ophthalmol 1999; 128:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5246 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36856=[""].join("\n");
var outline_f35_63_36856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Midbrain lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Subarachnoid space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cavernous sinus lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Superior orbital fissure/Orbital lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nonisolated third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Isolated third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119291787\">",
"      - Evaluation for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119291508\">",
"      - Complete external dysfunction with normal internal function (pupil-sparing complete third nerve palsy)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119291515\">",
"      - Third nerve palsy with complete internal dysfunction (pupil-involved) and complete or incomplete external dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119291523\">",
"      - Other patterns of isolated third nerve deficits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119291530\">",
"      - Isolated third nerve palsy with signs of aberrant regeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Persistent deficits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/60/7110\" title=\"figure 1\">",
"      Third nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5246|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/3/37936\" title=\"picture 1\">",
"      Nonpupil-sparing 3rd nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/59/21431\" title=\"picture 2\">",
"      Partial third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/4/30796\" title=\"table 1\">",
"      Causes of third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/17/13596\" title=\"table 2\">",
"      Aneurysm risk in CN3 palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=related_link\">",
"      Approach to the patient with anisocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=related_link\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25320?source=related_link\">",
"      Overview of diplopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31255?source=related_link\">",
"      Overview of ptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36857="Etiology and evaluation of hypernatremia";
var content_f35_63_36857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of hypernatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36857/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/63/36857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is a relatively common problem. As an example, the prevalence of hypernatremia in a study of 981 adults hospitalized in an intensive care unit was 9 percent: 2 percent had hypernatremia on admission; and 7 percent developed hypernatremia during their hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/1\">",
"     1",
"    </a>",
"    ]. Hypernatremia primarily occurs in patients who do not experience or respond to thirst normally due to impaired mental status (eg, elderly and critically ill patients) and in infants who can experience thirst but require others to provide fluid intake. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The importance of thirst'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As described below, hypernatremia is most often due to water loss, but can also be caused by the intake of salt without water or the administration of hypertonic sodium solutions. Hypernatremia due to water loss is called",
"    <strong>",
"     dehydration",
"    </strong>",
"    . This is different from",
"    <strong>",
"     hypovolemia",
"    </strong>",
"    , in which both salt and water are lost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes and evaluation of hypernatremia will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef69879 \" href=\"mobipreview.htm?27/22/28011\">",
"     table 1",
"    </a>",
"    ). The treatment of patients with hypernatremia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to discussing the etiology and evaluation of hypernatremia, it is helpful to review the determinants of the serum sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190652569\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF THE SERUM SODIUM CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the factors that determine the serum sodium concentration is required to appreciate which fluid losses promote the development of hypernatremia and what the composition of intravenous fluids must be to correct the hypernatremia. As an example, how can vomiting or diarrhea, both of which lead to fluid loss that is isosmotic to plasma, induce hypernatremia? In addition, why does the addition of potassium salts (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ) to an intravenous solution of 5 percent dextrose in water diminish the degree to which this solution with lower the serum sodium?",
"   </p>",
"   <p>",
"    In the following discussion, the term &ldquo;tonicity&rdquo; (also called the effective plasma osmolality) refers to the activity of solutes that do not easily cross cell membranes and therefore determine the transcellular distribution of water. &nbsp;",
"   </p>",
"   <p>",
"    The extracellular and intracellular fluids are in osmotic equilibrium since water moves freely across most cell membranes. As a result, plasma tonicity is equal to the effective intracellular osmolality and to the effective osmolality of the total body water (TBW). These relationships can be summarized by the following equation:",
"   </p>",
"   <p>",
"    &nbsp;Plasma tonicity &nbsp;= &nbsp;(Extracellular solute &nbsp;+ &nbsp;Intracellular solute)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; TBW",
"   </p>",
"   <p>",
"    Exchangeable sodium salts (Nae) are the primary effective extracellular solute and exchangeable potassium (Ke) and its associated intracellular anions are the primary intracellular solutes; these solutes are the major determinants of the effective plasma osmolality. Glucose, the other major extracellular solute is, in the absence of marked hyperglycemia, present in a much lower molar concentration than sodium (eg, 5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [90",
"    <span class=\"nowrap\">",
"     mg/dL]",
"    </span>",
"    versus 140",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 30 percent of total body sodium and a smaller fraction of total body potassium are bound in areas such as bone where they are &ldquo;nonexchangeable&rdquo; and therefore not osmotically active. In addition, urea is considered an ineffective osmole, since it freely equilibrates across the cell membranes. When the plasma concentration of an ineffective osmole changes, the solute rapidly moves into or out of cells to equalize those concentrations. Thus, there is little or no water shift into or out of the cells as occurs with changes in the plasma sodium concentration",
"   </p>",
"   <p>",
"    Thus, plasma tonicity (effective plasma osmolality) can be expressed as:",
"   </p>",
"   <p>",
"    &nbsp;Plasma tonicity &nbsp;&asymp; &nbsp; (2 x Nae &nbsp;+ &nbsp;2 x Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;TBW",
"   </p>",
"   <p>",
"    The multiplier 2 accounts for the osmotic contributions of the anions accompanying sodium and potassium. In the absence of marked hyperglycemia or the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , the above equation can be simplified to:",
"   </p>",
"   <p>",
"    &nbsp;2 x plasma Na &nbsp;&asymp; &nbsp;(2 x Nae &nbsp;+ &nbsp;2 x Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;TBW",
"   </p>",
"   <p>",
"    and then to:",
"   </p>",
"   <p>",
"    &nbsp;Plasma Na &nbsp;&asymp; &nbsp;(Nae &nbsp;+ &nbsp;Ke)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;TBW",
"   </p>",
"   <p>",
"    As shown in the figure, this relationship applies over a wide range of plasma or serum sodium concentrations (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"mobipreview.htm?42/31/43518\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190652576\">",
"    <span class=\"h2\">",
"     Application to hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is most often due to unreplaced water loss, but can also be induced by the administration of hypertonic saline or the ingestion sodium chloride. The intake of potassium without water will have the same effect on the serum sodium as the intake of sodium without water. As an example, the administration of potassium to treat hypokalemia will raise the serum potassium concentration. However, most of the administered potassium will enter the cells, which will cause the osmotic movement of water from the extracellular fluid into the cells, resulting in a small increase in serum sodium unless there is concurrent water intake.",
"   </p>",
"   <p>",
"    The importance of the sodium plus potassium in lost body fluids as a determinant of the serum sodium concentration (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"mobipreview.htm?42/31/43518\">",
"     figure 1",
"    </a>",
"    ) can be illustrated by considering the composition of various gastrointestinal fluids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with secretory diarrheas (cholera, VIPoma) have a sodium plus potassium concentration in the diarrheal fluid that is similar to the plasma sodium concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Loss of this fluid will lead to both a fall in extracellular fluid volume and potassium depletion, but will not directly affect the serum sodium concentration.",
"     </li>",
"     <li>",
"      In contrast, many viral and bacterial enteritides and the osmotic diarrhea induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      (to treat hepatic encephalopathy) or charcoal-sorbitol (to treat a drug overdose) are associated with an isosmotic diarrheal fluid that has a sodium plus potassium concentration between 40 and 100",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ]; organic solutes, which do not affect the serum sodium concentration, make up the remaining osmoles. Unreplaced loss of this fluid will tend to induce hypernatremia, because water is being lost in excess of sodium plus potassium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/6,8\">",
"       6,8",
"      </a>",
"      ]. Similar considerations apply to urinary losses during an osmotic diuresis induced by glucose,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , or urea (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The sodium plus potassium concentration in vomitus and sweat is similar to that in nonsecretory forms of diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In one study, for example, the sodium plus potassium concentration in gastric fluid was well below that of the plasma, averaging about 50 to 55 meq [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/11\">",
"       11",
"      </a>",
"      ]. Thus, loss of this fluid will tend to raise the serum sodium even though the fluid is isosmotic to plasma. Hydrochloric acid (HCl) accounts for most of the gap between the osmolality of gastric fluid and the contributions of sodium and potassium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/11\">",
"       11",
"      </a>",
"      ]. The loss of HCl has no effect on the serum sodium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, when considering either the etiology or treatment of hypernatremia, it is the",
"    <strong>",
"     sodium plus potassium",
"    </strong>",
"    concentration in the fluid lost or the fluid given,",
"    <strong>",
"     not the osmolality",
"    </strong>",
"    , that determines the effect on the serum sodium. In patients who are both hypernatremic and hypokalemic, the addition of potassium to the administered fluid will diminish the amount of electrolyte-free water that is given, thereby limiting the reduction in serum sodium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24393?source=see_link&amp;anchor=H21881413#H21881413\">",
"     \"Treatment of hypernatremia\", section on 'Concurrent electrolyte replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE IMPORTANCE OF THIRST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can be produced by either the administration of hypertonic sodium solutions or, much more commonly, by the loss of electrolyte-free water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/1,14-18\">",
"     1,14-18",
"    </a>",
"    ]. However, salt intake and water loss seldom result in hypernatremia, because the ensuing rise in plasma osmolality stimulates both the release of antidiuretic hormone (ADH) and thirst, thereby minimizing further water loss and increasing water intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/14,18,19\">",
"     14,18,19",
"    </a>",
"    ]. The decrease in water loss and increase in water intake then lower the serum sodium concentration back to normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This regulatory system is so efficient that the plasma osmolality is maintained within a range of 1 to 2 percent despite wide variations in sodium and water intake. Even patients with diabetes insipidus maintain a near-normal serum sodium concentration by appropriately increasing water intake to replace large urinary water losses caused by diminished ADH effect.",
"   </p>",
"   <p>",
"    As a result, hypernatremia is seen primarily in patients who cannot experience or respond to thirst normally due to impaired mental status (eg, elderly or critically ill patients) and in infants who can experience thirst but require others to provide fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/1,14-17,20\">",
"     1,14-17,20",
"    </a>",
"    ]. In a retrospective review of 103 hospitalized adults who had hypernatremia on admission or developed it after admission, 86 percent lacked free access to water, 94 percent received less than 1000 mL of electrolyte-free water per day, and many had impaired water conservation due to decreased concentrating ability (primarily due to diuretic therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/15\">",
"     15",
"    </a>",
"    ]. Elderly patients also appear to have diminished osmotic stimulation of thirst via an unknown mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalized patients, whether old or young, can become hypernatremic as a result of an inadequate fluid prescription",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired thirst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. The above retrospective review included 85 adults with hospital-acquired hypernatremia, 94 percent of whom received less than one liter of electrolyte-free fluid per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/15\">",
"     15",
"    </a>",
"    ]. Many hospitalized elderly patients also develop volume depletion because of sodium and water losses due to diuretics, vomiting, or diarrhea coupled with reduced intake.",
"   </p>",
"   <p>",
"    Individuals who are alert and have access to water should not develop hypernatremia. Alert patients who are not thirsty despite a serum sodium concentration of 150",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more have, by definition, a hypothalamic lesion affecting the thirst center. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141685781\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF HYPERNATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major mechanisms by which hypernatremia can occur: unreplaced water loss, which is responsible for most cases; water loss into cells; and sodium overload. However, persistent hypernatremia should not occur in patients who are alert, have an intact thirst mechanism, and have access to water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Unreplaced water loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of solute-free water will, if unreplaced, lead to an elevation in the serum sodium concentration. As described above, the serum sodium concentration and osmolality are determined by the ratio between total body effective osmoles (primarily sodium and potassium salts) and the total body water (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"mobipreview.htm?42/31/43518\">",
"     figure 1",
"    </a>",
"    ). Loss of fluid with a",
"    <strong>",
"     sodium plus potassium concentration less than that in the plasma",
"    </strong>",
"    will, if the water loss is not replaced, raise the serum sodium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H190652569\">",
"     'Determinants of the serum sodium concentration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H190652576\">",
"     'Application to hypernatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a variety of sources of electrolyte-free water loss that can lead to hypernatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/18\">",
"     18",
"    </a>",
"    ]. These include skin, gastrointestinal, and urinary losses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Skin losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water loss from the skin consists of both insensible (transepidermal by diffusion) and sensible (sweat) losses and is important for thermoregulation. Under normal conditions, the volume of sweat is about 500 to 700",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in adults. However, sweat losses are increased dramatically by fever, exercise, and exposure to high temperatures.",
"   </p>",
"   <p>",
"    Sweat is derived from the extracellular fluid and most of the sodium is then removed by the sweat glands. The normal mean sweat sodium concentration is about 38 to 45",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (range 24 to 65",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and the mean sweat potassium concentration is about 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As the rate of sweat production increases, the sodium concentration rises since the capacity of sweat glands to increase sodium reabsorption is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. Thus, sweat is hypotonic to plasma (ie, lower sodium plus potassium concentration) which will promote free water loss.",
"   </p>",
"   <p>",
"    The obligatory water loss from sweat and transdermal evaporative losses must be replaced to avoid hypernatremia. As an example, exclusively breast-fed neonates with a weight loss of more than 10 percent of birth weight are at risk for hypernatremia if inadequate breast-feeding fails to replace ongoing insensible water losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to water loss in sweat or from evaporation, water that enters alveolar air and is eliminated by breathing does",
"    <strong>",
"     not",
"    </strong>",
"    result in net water loss from the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/30\">",
"     30",
"    </a>",
"    ]. Partial pressures of water and CO2 are nearly identical in alveolar air in patients with a normal arterial pCO2, and thus are eliminated in a 1:1 ratio. Because water and CO2 are produced in a 1:1 ratio by metabolism of carbohydrates and fatty acids, the loss of water through respiration is equal to its metabolic production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Gastrointestinal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both upper and lower gastrointestinal losses can result in hypernatremia when water intake is limited. As mentioned above, loss of gastric secretions (due to vomiting or drainage) and upper gastrointestinal losses, which contain both gastric and small intestinal secretions, have a sodium plus potassium concentration well below that in the plasma and will therefore promote the development of hypernatremia. Similar considerations apply to osmotic diarrheas but not to secretory diarrheas, which have a sodium plus potassium concentration similar to that in the plasma, the loss of which will not directly affect the serum sodium concentration. (See",
"    <a class=\"local\" href=\"#H190652576\">",
"     'Application to hypernatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698806827\">",
"    <span class=\"h3\">",
"     Urinary losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free water loss in the urine can lead to hypernatremia if not replaced. This is most often a problem in patients with diabetes insipidus or an osmotic diuresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Central or nephrogenic diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased release of antidiuretic hormone (ADH) or renal resistance to its effect (central and nephrogenic diabetes insipidus, respectively) causes the excretion of a relatively dilute urine. Most patients with diabetes insipidus have a normal thirst mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/31\">",
"     31",
"    </a>",
"    ]. As a result, they typically present with polyuria and polydipsia, and a high-normal serum sodium concentration, which is required to stimulate thirst. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, marked and symptomatic hypernatremia can occur in patients with diabetes insipidus if a central lesion impairs both ADH release and thirst, in infants and young children who cannot independently access free water, or in the postoperative period in patients with unrecognized diabetes insipidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H92106445\">",
"     'Adipsic diabetes insipidus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Osmotic diuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An osmotic diuresis due to nonreabsorbed, nonelectrolyte solutes such as glucose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or urea increases the output of urine that has a sodium plus potassium concentration well below serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The loss of such fluid would be expected to raise the serum sodium concentration. However, the changes in plasma osmolality and serum sodium concentration associated with osmotic diuresis are complex:",
"   </p>",
"   <p>",
"    As an example, patients with diabetic ketoacidosis or nonketotic hyperglycemia present with a high serum osmolality due to both hyperglycemia and the osmotic diuresis. However, the serum sodium concentration is variable, reflecting the balance between the hyperglycemia-induced increase in serum tonicity, which promotes water movement out of the cells that will lower the serum sodium, and the glucosuria-induced osmotic diuresis, which will tend to raise the serum sodium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar considerations apply to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    therapy. The initial rise in serum mannitol will lower the serum sodium due to osmotic water movement out of the cells. However, in the absence of impaired renal function, mannitol is rapidly excreted in the urine and the associated osmotic diuresis will raise the serum sodium due both to the removal of mannitol from the plasma, which will allow water to move back into the cells, and to the osmotic diuresis, which will cause water loss in excess of sodium plus potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of mannitol therapy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike hyperglycemia and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    therapy, patients who have an osmotic diuresis due to urea (which most commonly occurs during the resolution of azotemia) can produce hypernatremia but not hyponatremia. Because urea is an ineffective osmole, water does not move out of cells, and therefore the elevated serum urea concentrations do not lower the serum sodium. As urea is excreted in the urine, the loss of water in the urine will raise the serum sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypothalamic lesions affecting thirst or osmoreceptor function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can occur in the absence of increased water losses if there is primary hypothalamic disease impairing thirst (hypodipsia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A defect in thirst with or without concomitant diabetes insipidus can be seen in children with either congenital or acquired hypothalamic structural lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. As an example, infants with holoprosencephaly (dysplasia of the brain midline structures) may show no signs of thirst even when their serum osmolality exceeds 330",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In such patients, forced water intake is usually sufficient to maintain a normal serum sodium concentration, although central diabetes insipidus, if present, must also be treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92106445\">",
"    <span class=\"h4\">",
"     Adipsic diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ADH secretion and thirst are both impaired, affected patients are vulnerable to recurrent episodes of hypernatremia. Once called essential hypernatremia, this disorder is now called adipsic diabetes insipidus or central diabetes insipidus with deficient thirst. Causes of adipsic diabetes insipidus include a variety of congenital and acquired central nervous system lesions, with the most common being septo-optic dysplasia, germinoma, rupture or clipping aneurysms of the anterior communicating artery of the circle of Willis, craniopharyngioma, and central nervous system sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/32,38,39\">",
"     32,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adipsic diabetes insipidus was once thought to result from an upward resetting of the osmostat, such that a higher osmolality was recognized as normal. This hypothesis was based upon the observation that giving these patients water reduced ADH release. However, subsequent studies showed that the water-induced suppression of ADH was due to mild volume expansion rather than a fall in serum osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/18,40,41\">",
"     18,40,41",
"    </a>",
"    ]. True upward resetting of the osmostat has been described only in patients with primary mineralocorticoid excess (such as primary aldosteronism). It is presumed that the suppressive effect of chronic mild volume expansion on ADH release is responsible for the resetting; the serum sodium concentration in these patients is usually between 143 and 147",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features of primary aldosteronism\", section on 'Mild hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with adipsic DI typically have moderate to severe hypernatremia with the serum sodium in one review ranging from 155 to 190",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/32\">",
"     32",
"    </a>",
"    ]. Most of these patients are asymptomatic because the hypernatremia is chronic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all patients with adipsic DI, a careful neurologic and radiologic evaluation should be performed, looking for a possible treatable disease (such as a benign tumor) that might restore osmoreceptor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12664565\">",
"    <span class=\"h5\">",
"     Treatment of adipsic DI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy of patients with adipsic DI is uncertain. Urinary water losses can be controlled with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , as in patients with central diabetes insipidus who have intact thirst. However, with no sense of thirst as a guide, both hyponatremia from too much fluid intake and hypernatremia from too little fluid intake are common. The goal of therapy is to maintain a serum sodium concentration between 130 and 150",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    Many",
"    patients can be taught to regulate their water intake using a sliding scale based upon body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/44\">",
"     44",
"    </a>",
"    ]. If the patient has complete DI, we have given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    as often as three times daily to minimize urine losses and therefore limit variability. The body weight at which the serum sodium concentration is normal is determined periodically and the daily water prescription required to maintain a constant body weight and a serum sodium concentration within the target range is determined by trial and error. Deviations from the established ideal weight are then used to modify the water prescription for that day, decreasing or increasing water intake by 500 mL for every 0.5 kg deviation in body weight. A deviation of more than 3 percent of body weight in either direction is an indication to check the serum sodium concentration.",
"   </p>",
"   <p>",
"    Daily measurements of the serum sodium may be necessary, particularly in young children and adults with cognitive impairment who cannot regulate their own water intake to achieve the goal body weight. Point-of-care devices capable of measuring the serum sodium on finger stick specimens can be used.",
"   </p>",
"   <p>",
"    There is some evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    , which increases the renal effect of ADH, can also improve impaired thirst in patients with central diabetes insipidus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/31/505?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of central diabetes insipidus\", section on 'Chlorpropamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Water loss into cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient hypernatremia (in which the serum sodium concentration can rise by as much as 10 to 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within a few minutes) can be induced by severe exercise or electroshock induced seizures, an effect that is mediated by a transient increase in cell osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Breakdown of large complex organic molecules into numerous small components is thought to be at least in part responsible for the increase in cell osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum sodium concentration returns to normal within 5 to 15 minutes after the cessation of exertion or seizure activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sodium overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and often marked hypernatremia (in which the serum sodium concentration can exceed 200",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can be induced by the administration of hypertonic sodium solutions. Examples include accidental or nonaccidental salt poisoning in infants and young children, the infusion of hypertonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to treat metabolic acidosis, administration of hypertonic saline to patients with traumatic head injury, hypertonic saline irrigation of hydatid cysts, systemic absorption of intrauterine hypertonic saline administered to induce abortion, and massive salt ingestion as can occur with a highly concentrated saline emetic or gargle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/50-56\">",
"     50-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254062278\">",
"    <span class=\"h3\">",
"     Salt poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salt poisoning is an infrequent problem that primarily occurs in infants and young children but has been reported in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/57\">",
"     57",
"    </a>",
"    ]. The following scenarios have been described in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surreptitious intentional salt poisoning is one of the more common forms of child abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/50\">",
"       50",
"      </a>",
"      ]. A teaspoon of salt contains 100 meq of Na, which can increase the serum sodium concentration in a 10 kg child by 17",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      The accidental substitution of salt for sugar in infant formulas resulted in an epidemic of severe hypernatremia in a hospital nursery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In parts of Turkey, the custom of &ldquo;salting&rdquo; of newborns by grandparents, who scrub the baby&rsquo;s entire body with table salt for an hour, can lead to systemic absorption of salt through the traumatized skin, possibly causing severe hypernatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Salt poisoning causes a rapid onset of hypernatremia, often resulting in cerebral hemorrhage and irreversible neurologic injury. Osmotic demyelination can occur, similar to the injury caused by a rapid elevation in serum sodium in patients with chronic hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salt poisoning has a number of distinguishing features from unreplaced water loss which, as noted above, is the most common cause of hypernatremia (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Unreplaced water loss'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salt poisoning is initially associated with weight gain, due to the stimulation of both thirst, which increases fluid intake, and ADH release, which diminishes water loss. On the other hand, unreplaced water losses severe enough to produce hypernatremia are associated with weight loss. However, there are two potential limitations to the use of changes in body weight. First, this distinction requires accurate knowledge of the child&rsquo;s baseline weight, which may not be available. Second, weight gain with salt poisoning requires access to water. If the child does not drink, there may actually be a reduction in body weight due to the osmotic diuresis induced by excretion of the excess sodium.",
"     </li>",
"     <li>",
"      Sodium excretion is appropriately increased with salt poisoning and is appropriately reduced with hypovolemia due to unreplaced water losses. The urine sodium concentration may be misleading since a highly concentrated urine due to hypernatremia-induced stimulation of ADH release can raise an appropriately low urine sodium concentration to a value that might be consistent with euvolemia.",
"     </li>",
"     <li>",
"      The fractional excretion of sodium (FENa) may be more accurate than the urine sodium concentration since it is not affected by the urine volume. It has been suggested that, in infants and young children with hypernatremia and normal renal function, a FENa greater than 2 percent is strongly suggestive of salt poisoning and values between 1 and 2 percent are consistent with the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In contrast, in patients with relatively normal renal function, a FENa less than 0.1 to 0.2 percent is suggestive of hypernatremia caused by water loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/62\">",
"       62",
"      </a>",
"      ]. A similar finding would be expected with a late presentation of salt poisoning, after the administered salt has been excreted and hypovolemia has been induced by the osmotic diuresis, or if the patient has concomitant salt poisoning and hypovolemia.",
"      <br/>",
"      <br/>",
"      One problem with the use of the FENa is that the values that define volume depletion vary with the filtered sodium load, which is determined by the glomerular filtration rate. The FENa that defines hypovolemia progressively rises toward 1 percent in patients with increasingly impaired renal function. These issues are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=see_link\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92923799\">",
"    <span class=\"h4\">",
"     Treatment of salt poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of hypernatremia is typically less than 24 hours by the time patients with salt poisoning are seen by a physician. At this time, the cerebral adaptation to hypernatremia is incomplete, minimizing any risk of neurologic injury from overly rapid correction of the hypernatremia, as can occur in chronic hypernatremia. Thus, the initial therapy is directed at rapid reduction in the serum sodium concentration to reduce the neurologic risk of prolonged severe hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest lowering the serum sodium by approximately 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per hour in an attempt to reach a near normal level within 24 hour. Rapid correction of hypernatremia can be accomplished in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid infusion of 2.5 percent dextrose in water &mdash; The initial rate at which this fluid should be administered can be calculated from the estimated water deficit plus estimated ongoing fluid losses (mostly insensible losses). This issue is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24393?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of hypernatremia\", section on 'Step one: estimate the water deficit'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24393?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of hypernatremia\", section on 'Step three: design a fluid repletion regimen'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A 2.5 percent solution is preferred to the usual 5 percent solution to minimize the risk of hyperglycemia, even in patients without diabetes mellitus, due to the high glucose load with large volumes of dextrose in water. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link&amp;anchor=H17#H17\">",
"       \"Maintenance and replacement fluid therapy in adults\", section on 'Dextrose-induced hyperglycemia'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Acute dialysis &mdash; Patients with acute salt poisoning occasionally develop acute kidney injury and oliguria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/53\">",
"       53",
"      </a>",
"      ]. In such patients, dialysis should be used to rapidly reduce the serum sodium while avoiding fluid overload [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of acute salt poisoning is poor regardless of the treatment chosen, most likely because treatment is initiated after irreversible neurologic injury has already occurred. In a review of 30 cases of acute salt poisoning, overall mortality was greater than 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/53\">",
"     53",
"    </a>",
"    ]. The survival rate was better in young children and with lesser degrees of hypernatremia. Neither the rate of correction of the serum sodium nor the type of therapy (hypotonic fluids versus dialysis) predicted survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254062285\">",
"    <span class=\"h3\">",
"     Iatrogenic sodium loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of isotonic saline to match hypotonic fluid losses causes hypernatremia by net salt gain, equivalent to the effect of administering hypertonic saline. This scenario can occur during the treatment of various common disorders, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncontrolled diabetes, in which an osmotic diuresis from nonreabsorbed glucose is replaced with isotonic solutions.",
"     </li>",
"     <li>",
"      Recovery from severe azotemia, in which a urea (osmotic) diuresis is replaced with isotonic saline.",
"     </li>",
"     <li>",
"      Nasogastric suction, in which patients often receive isotonic saline to replace fluid losses that have sodium plus potassium concentrations well below that of plasma. (See",
"      <a class=\"local\" href=\"#H190652576\">",
"       'Application to hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Edematous, critically ill patients who have received large volumes of saline and then receive loop diuretic therapy, which impairs renal concentrating ability resulting in inappropriately high water losses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6017462\">",
"    <span class=\"h1\">",
"     EVALUATION OF HYPERNATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of the hypernatremia is usually evident from the history. In adults, it is most often due to water losses in older patients whose losses are not replaced because of impaired mental status (",
"    <a class=\"graphic graphic_table graphicRef69879 \" href=\"mobipreview.htm?27/22/28011\">",
"     table 1",
"    </a>",
"    ). On the other hand, a hypothalamic lesion affecting the thirst center should be strongly suspected in an alert patient with access to water who has a serum sodium concentration above 150",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6017722\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the etiology of hypernatremia is unclear, the diagnosis can usually be established by measurement of the urine osmolality and, if the urine osmolality is less than 600",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    observing the change in urine osmolality after administration of exogenous antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rise in the serum sodium concentration is associated with a rise in the plasma osmolality, which is a potent stimulus to both ADH release and thirst (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"mobipreview.htm?14/61/15325\">",
"     figure 2",
"    </a>",
"    ). A plasma osmolality above 295",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (which represents a serum sodium concentration above 145 to 147",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    generally leads to sufficient ADH secretion to maximally stimulate urinary concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, if both hypothalamic and renal function are intact, the urine osmolality in the presence of hypernatremia should be above 600",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and, if given, exogenous ADH should",
"    <strong>",
"     not",
"    </strong>",
"    produce a further rise in the urine osmolality. These basic principles permit the following approach to identifying the cause of hypernatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urine osmolality is low or intermediate",
"      </strong>",
"      ��� If the urine osmolality is less than the plasma osmolality (usually less than 300",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      then the patient has either central or nephrogenic diabetes insipidus (DI). These disorders can be distinguished by the administration of exogenous ADH followed by monitoring of the urine osmolality and volume every 30 minutes over the next two hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnosis of polyuria and diabetes insipidus\", section on 'Water restriction test'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the urine osmolality is intermediate (between 300 to 600",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      the hypernatremia may be due to an osmotic diuresis or to DI. In such patients, the presence of an osmotic diuresis can be confirmed by measuring total solute excretion (equal to the product of the urine osmolality and the daily urine volume). The normal value on a regular diet is 600 to 900 mosmol per day (consisting primarily of sodium, potassium, ammonium salts, and urea). A value well above 1000 mosmol per day suggests at least a contribution from increased solute excretion. Patients with an osmotic diuresis and hypernatremia will not respond to exogenous ADH, since the endogenous effect is already maximal. If an osmotic diuresis is not present, an evaluation to rule out DI should be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis of polyuria and diabetes insipidus\", section on 'Solute diuresis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnosis of polyuria and diabetes insipidus\", section on 'Water restriction test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urine osmolality is high",
"      </strong>",
"      ��� If the urine osmolality is above 600",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      then both the secretion of and response to endogenous ADH are intact. In this setting, unreplaced gastrointestinal, renal, or insensible losses are present or, rarely, sodium overload or a primary defect in thirst may be responsible for the hypernatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/65\">",
"       65",
"      </a>",
"      ]. Measurement of the urine sodium concentration may help to distinguish among these disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The urine sodium should be less than 25",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      when water loss and volume depletion are the primary problems, as with vomiting or diarrhea. However, values somewhat higher than 25",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      do not necessarily exclude hypovolemia, since there may also be a high rate of water reabsorption; in this setting, the rate of sodium excretion is low but the urine sodium concentration is higher than expected due to a low urine volume. Calculation of the fractional excretion of sodium (FENa), using either standard units (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?25/13/25809?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or SI units (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?24/28/25025?source=see_link\">",
"       calculator 2",
"      </a>",
"      ), may be helpful since it eliminates the effect of urine volume. However, the FENa value used to define hypovolemia is much lower than the 1 percent cutoff used in acute kidney injury. In patients with a normal glomerular filtration rate, for example, the FENa cutoff may be less than 0.1 percent because of the high filtered sodium load. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link&amp;anchor=H780669#H780669\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Urine sodium concentration'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=see_link\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The urine sodium is typically well above 100",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      following the ingestion of salt or infusion of a hypertonic sodium solution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36857/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25210825\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia is a relatively common problem particularly among young children, the elderly, and critically ill who depend upon others to control their water intake. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypernatremia occurs when osmotically active electrolytes (sodium and potassium) are retained without water, when water is lost without these electrolytes, or a combination of these two. (See",
"      <a class=\"local\" href=\"#H190652569\">",
"       'Determinants of the serum sodium concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salt intake and water loss seldom result in hypernatremia, because the ensuing rise in plasma osmolality stimulates the release of both antidiuretic hormone (ADH) and thirst, thereby minimizing further water loss and increasing water intake. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The importance of thirst'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loss of body fluids with a sodium plus potassium concentration lower than the serum sodium will increase the serum sodium concentration if these losses are unreplaced. Common examples of hypotonic losses include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Upper gastrointestinal fluid (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastrointestinal losses'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Diarrhea caused by osmotic cathartics like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      or infections (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastrointestinal losses'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Urinary losses due to diabetes insipidus, glycosuria, urea, and osmotic or loop diuretics (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Osmotic diuresis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia can occur in the absence of increased water losses if there is primary hypothalamic disease impairing thirst (hypodipsia), sometimes associated with concurrent diabetes insipidus (adipsic diabetes insipidus). In such patients, forced water intake is usually sufficient to maintain a normal serum sodium concentration, although in patients with adipsic diabetes insipidus,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      must also be given. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12664565\">",
"       'Treatment of adipsic DI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient hypernatremia can develop after seizures or intense exercise. The ensuing increase in intracellular osmolality via break down of glycogen into smaller more osmotically active molecules leads to internal shift of water into cells. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Water loss into cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute and often marked hypernatremia can be induced by massive salt ingestion or administration of hypertonic sodium-containing solutions. In such patients, initial therapy is directed at rapid reduction in the serum sodium concentration to reduce the neurologic risk of prolonged severe hypernatremia. (See",
"      <a class=\"local\" href=\"#H254062278\">",
"       'Salt poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of isotonic saline to match hypotonic fluid losses causes hypernatremia by net salt gain, equivalent to the effect of administering hypertonic saline. This scenario commonly occurs during the treatment of uncontrolled diabetes, recovering azotemia, nasogastric suction, and critically ill patients who have received large amounts of saline and subsequently treated for edema using loop diuretics. (See",
"      <a class=\"local\" href=\"#H254062285\">",
"       'Iatrogenic sodium loading'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of the hypernatremia is usually evident from the history. In adults, it is most often due to water losses in older patients that are not replaced because of impaired mental status (",
"      <a class=\"graphic graphic_table graphicRef69879 \" href=\"mobipreview.htm?27/22/28011\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6017462\">",
"       'Evaluation of hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the etiology of hypernatremia is unclear, the diagnosis can usually be established by measurement of the urine osmolality and, if the urine osmolality is less than 600",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      observing the change in urine osmolality after administration of exogenous ADH. (See",
"      <a class=\"local\" href=\"#H6017722\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/1\">",
"      Lindner G, Funk GC, Schwarz C, et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis 2007; 50:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/2\">",
"      Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med 1997; 127:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/3\">",
"      EDELMAN IS, LEIBMAN J, O'MEARA MP, BIRKENFELD LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/4\">",
"      Shiau YF, Feldman GM, Resnick MA, Coff PM. Stool electrolyte and osmolality measurements in the evaluation of diarrheal disorders. Ann Intern Med 1985; 102:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/5\">",
"      Castro-Rodr&iacute;guez JA, Salazar-Lindo E, Le&oacute;n-Bar&uacute;a R. Differentiation of osmotic and secretory diarrhoea by stool carbohydrate and osmolar gap measurements. Arch Dis Child 1997; 77:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/6\">",
"      Nelson DC, McGrew WR Jr, Hoyumpa AM Jr. Hypernatremia and lactulose therapy. JAMA 1983; 249:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/7\">",
"      Allerton JP, Strom JA. Hypernatremia due to repeated doses of charcoal-sorbitol. Am J Kidney Dis 1991; 17:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/8\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/9\">",
"      GIPSTEIN RM, BOYLE JD. HYPERNATREMIA COMPLICATING PROLONGED MANNITOL DIURESIS. N Engl J Med 1965; 272:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/10\">",
"      Gault MH, Dixon ME, Doyle M, Cohen WM. Hypernatremia, azotemia, and dehydration ue to high-protein tube feeding. Ann Intern Med 1968; 68:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/11\">",
"      Austin JH, Gammon GD. GASTRIC SECRETION AFTER HISTAMINE: SODIUM AND POTASSIUM CONTENT AND PEPSIN ESTIMATION. J Clin Invest 1931; 10:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/12\">",
"      CONSOLAZIO CF, MATOUSH LO, NELSON RA, et al. Excretion of sodium, potassium, magnesium and iron in human sweat and the relation of each to balance and requirements. J Nutr 1963; 79:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/13\">",
"      Henkin SD, Sehl PL, Meyer F. Sweat rate and electrolyte concentration in swimmers, runners, and nonathletes. Int J Sports Physiol Perform 2010; 5:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/14\">",
"      Adrogu&eacute; HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/15\">",
"      Palevsky PM, Bhagrath R, Greenberg A. Hypernatremia in hospitalized patients. Ann Intern Med 1996; 124:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/16\">",
"      Snyder NA, Feigal DW, Arieff AI. Hypernatremia in elderly patients. A heterogeneous, morbid, and iatrogenic entity. Ann Intern Med 1987; 107:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/17\">",
"      Sterns RH. Hypernatremia in the intensive care unit: instant quality--just add water. Crit Care Med 1999; 27:1041.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 749-761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/19\">",
"      Robertson GL. Abnormalities of thirst regulation. Kidney Int 1984; 25:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/20\">",
"      Liamis G, Tsimihodimos V, Doumas M, et al. Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. Nephrol Dial Transplant 2008; 23:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/21\">",
"      Phillips PA, Bretherton M, Johnston CI, Gray L. Reduced osmotic thirst in healthy elderly men. Am J Physiol 1991; 261:R166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/22\">",
"      Phillips PA, Rolls BJ, Ledingham JG, et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 1984; 311:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/23\">",
"      Moritz ML, Ayus JC. The changing pattern of hypernatremia in hospitalized children. Pediatrics 1999; 104:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/24\">",
"      SCHWARTZ IL, THAYSEN JH. Excretion of sodium and potassium in human sweat. J Clin Invest 1956; 35:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/25\">",
"      Patterson MJ, Galloway SD, Nimmo MA. Variations in regional sweat composition in normal human males. Exp Physiol 2000; 85:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/26\">",
"      CAGE GW, DOBSON RL. SODIUM SECRETION AND REABSORPTION IN THE HUMAN ECCRINE SWEAT GLAND. J Clin Invest 1965; 44:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/27\">",
"      Shamsuddin AK, Yanagimoto S, Kuwahara T, et al. Changes in the index of sweat ion concentration with increasing sweat during passive heat stress in humans. Eur J Appl Physiol 2005; 94:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/28\">",
"      Manganaro R, Mam&igrave; C, Marrone T, et al. Incidence of dehydration and hypernatremia in exclusively breast-fed infants. J Pediatr 2001; 139:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/29\">",
"      Oddie S, Richmond S, Coulthard M. Hypernatraemic dehydration and breast feeding: a population study. Arch Dis Child 2001; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/30\">",
"      Shafiee MA, Bohn D, Hoorn EJ, Halperin ML. How to select optimal maintenance intravenous fluid therapy. QJM 2003; 96:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/31\">",
"      Thompson CJ, Baylis PH. Thirst in diabetes insipidus: clinical relevance of quantitative assessment. Q J Med 1987; 65:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/32\">",
"      Mavrakis AN, Tritos NA. Diabetes insipidus with deficient thirst: report of a patient and review of the literature. Am J Kidney Dis 2008; 51:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/33\">",
"      McIver B, Connacher A, Whittle I, et al. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. BMJ 1991; 303:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/34\">",
"      Sze L, Ulrich B, Br&auml;ndle M. Severe hypernatraemia due to nephrogenic diabetes insipidus - a life-threatening side effect of chronic lithium therapy. Exp Clin Endocrinol Diabetes 2006; 114:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/35\">",
"      Hammond DN, Moll GW, Robertson GL, Chelmicka-Schorr E. Hypodipsic hypernatremia with normal osmoregulation of vasopressin. N Engl J Med 1986; 315:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/36\">",
"      Schaff-Blass E, Robertson GL, Rosenfield RL. Chronic hypernatremia from a congenital defect in osmoregulation of thirst and vasopressin. J Pediatr 1983; 102:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/37\">",
"      K&ouml;nig R, Beeg T, Tariverdian G, et al. Holoprosencephaly, bilateral cleft lip and palate and ectrodactyly: another case and follow up. Clin Dysmorphol 2003; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/38\">",
"      Crowley RK, Sherlock M, Agha A, et al. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 2007; 66:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/39\">",
"      Fabris A, Ronco C, Pellanda MV, et al. Fluctuation of vasopressin secretion in chronic hypernatremia. Nephron 1990; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/40\">",
"      DeRubertis FR, Michelis MF, Beck N, et al. \"Essential\" hypernatremia due to ineffective osmotic and intact volume regulation of vasopressin secretion. J Clin Invest 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/41\">",
"      DeRubertis FR, Michelis MF, Davis BB. \"Essential\" hypernatremia. Report of three cases and review of the literature. Arch Intern Med 1974; 134:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/42\">",
"      Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982; 72:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/43\">",
"      Gregoire JR. Adjustment of the osmostat in primary aldosteronism. Mayo Clin Proc 1994; 69:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/44\">",
"      Johnston S, Burgess J, McMillan T, Greenwood R. Management of adipsia by a behavioural modification technique. J Neurol Neurosurg Psychiatry 1991; 54:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/45\">",
"      Bode HH, Harley BM, Crawford JD. Restoration of normal drinking behavior by chlorpropamide in patients with hypodipsia and diabetes insipidus. Am J Med 1971; 51:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/46\">",
"      Nandi M, Harrington AR. Successful treatment of hypernatremic thirst deficiency with chlorpropamide. Clin Nephrol 1978; 10:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/47\">",
"      Felig P, Johnson C, Levitt M, et al. Hypernatremia induced by maximal exercise. JAMA 1982; 248:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/48\">",
"      Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/49\">",
"      WELT LG, ORLOFF J, KYDD DM, OLTMAN JE. An example of cellular hyperosmolarity. J Clin Invest 1950; 29:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/50\">",
"      MILLER NL, FINBERG L. Peritoneal dialysis for salt poisoning. Report of a case. N Engl J Med 1960; 263:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/51\">",
"      Meadow R. Non-accidental salt poisoning. Arch Dis Child 1993; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/52\">",
"      M&aacute;ttar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest. Am J Med 1974; 56:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/53\">",
"      Moder KG, Hurley DL. Fatal hypernatremia from exogenous salt intake: report of a case and review of the literature. Mayo Clin Proc 1990; 65:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/54\">",
"      Krige JE, Millar AJ, Rode H, Knobel D. Fatal hypernatraemia after hypertonic saline irrigation of hepatic hydatid cysts. Pediatr Surg Int 2002; 18:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/55\">",
"      Peterson B, Khanna S, Fisher B, Marshall L. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000; 28:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/56\">",
"      Kerenyi TD. Hypernatremia following intrauterine instillation of hypertonic saline solution. Report of a case and discussion. Obstet Gynecol 1969; 33:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/57\">",
"      Albi A, Baudin F, Matmar M, et al. Severe hypernatremia after hypertonic saline irrigation of hydatid cysts. Anesth Analg 2002; 95:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/58\">",
"      FINBERG L, KILEY J, LUTTRELL CN. Mass accidental salt poisoning in infancy. A study of a hospital disaster. JAMA 1963; 184:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/59\">",
"      Peker E, Kirimi E, Tuncer O, Ceylan A. Severe hypernatremia in newborns due to salting. Eur J Pediatr 2010; 169:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/60\">",
"      Dobato JL, Barriga FJ, Pareja JA, Vela L. [Extrapontine myelinolyses caused by iatrogenic hypernatremia following rupture of a hydatid cyst of the liver with an amnesic syndrome as sequela]. Rev Neurol 2000; 31:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/61\">",
"      Coulthard MG, Haycock GB. Distinguishing between salt poisoning and hypernatraemic dehydration in children. BMJ 2003; 326:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/62\">",
"      Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study. Clin J Am Soc Nephrol 2009; 4:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/63\">",
"      Sakai Y, Kato M, Okada T, et al. [Treatment of salt poisoning due to soy sauce ingestion with hemodialysis]. Chudoku Kenkyu 2004; 17:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36857/abstract/64\">",
"      Hoorn EJ, Betjes MG, Weigel J, Zietse R. Hypernatraemia in critically ill patients: too little water and too much salt. Nephrol Dial Transplant 2008; 23:1562.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 764-775.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2376 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-481C146FAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36857=[""].join("\n");
var outline_f35_63_36857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25210825\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190652569\">",
"      DETERMINANTS OF THE SERUM SODIUM CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190652576\">",
"      Application to hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE IMPORTANCE OF THIRST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141685781\">",
"      ETIOLOGY OF HYPERNATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Unreplaced water loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Skin losses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Gastrointestinal losses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H698806827\">",
"      - Urinary losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Central or nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Osmotic diuresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypothalamic lesions affecting thirst or osmoreceptor function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H92106445\">",
"      Adipsic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H12664565\">",
"      - Treatment of adipsic DI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Water loss into cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sodium overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H254062278\">",
"      - Salt poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H92923799\">",
"      Treatment of salt poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H254062285\">",
"      - Iatrogenic sodium loading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6017462\">",
"      EVALUATION OF HYPERNATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6017722\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25210825\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2376|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/31/43518\" title=\"figure 1\">",
"      Determinants of plasma sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/61/15325\" title=\"figure 2\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/22/28011\" title=\"table 1\">",
"      Major causes of hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36858="Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults";
var content_f35_63_36858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     Thomas M File, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/63/36858/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/63/36858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital-acquired (or nosocomial) pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP) are important causes of morbidity and mortality despite improved antimicrobial therapy, supportive care, and prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of HAP, VAP, and HCAP will be reviewed here. The diagnosis, epidemiology, pathogenesis, microbiology, risk factors, and prevention of HAP, VAP, and HCAP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pneumonia types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    guidelines distinguish the following types of pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital-acquired (or nosocomial) pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission.",
"     </li>",
"     <li>",
"      Ventilator-associated pneumonia (VAP) is a type of HAP that develops more than 48 to 72 hours after endotracheal intubation.",
"     </li>",
"     <li>",
"      Healthcare-associated pneumonia (HCAP) is defined as pneumonia that occurs in a non-hospitalized patient with extensive healthcare contact, as defined by one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days",
"     </li>",
"     <li>",
"      Residence in a nursing home or other long-term care facility",
"     </li>",
"     <li>",
"      Hospitalization in an acute care hospital for two or more days within the prior 90 days",
"     </li>",
"     <li>",
"      Attendance at a hospital or hemodialysis clinic within the prior 30 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HCAP was added as a category of pneumonia in the 2005",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines in order to identify patients at increased risk for MDR pathogens coming from community settings; such individuals would previously have been classified as having community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the definition of HCAP is being reevaluated since some authorities have argued that it is an overgeneralization to consider all HCAP patients at increased risk for MDR pathogens. The challenge for clinicians is to correctly identify the HCAP patient who is most likely to benefit from empiric treatment with broad-spectrum antibiotics with activity against MDR pathogens. The clinical issues surrounding HCAP are discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H249925653\">",
"     'Approach to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The guidelines can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     file://www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multidrug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of multidrug resistance (MDR) in gram-negative bacilli, which are an important cause of HAP, VAP, and HCAP, is variably defined as resistance to at least two, three, four, or eight of the antibiotics typically used to treat infections with these organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/4\">",
"     4",
"    </a>",
"    ]. Extensively-drug resistant (XDR) gram-negative bacilli are defined by resistance to all commonly used systemic antibiotics except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , and aminoglycosides. Awareness of local resistance patterns is critical for decisions regarding empiric therapy for HAP, VAP, and HCAP.",
"   </p>",
"   <p>",
"    Panresistance refers to those gram-negative organisms with diminished susceptibility to all of the antibiotics recommended for the empiric treatment of VAP, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Empiric treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Risk factors for multidrug resistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'MDR risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249925653\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate antibiotic therapy significantly improves survival for patients with hospital-acquired (or nosocomial) pneumonia (HAP), ventilator-associated pneumonia (VAP), or healthcare-associated pneumonia (HCAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. However, establishing the diagnosis of pneumonia in such patients can be difficult, especially those on mechanical ventilation in whom clinical, radiologic, and microbiologic findings can be due to numerous etiologies besides pneumonia. The difficulty in diagnosis may lead to overtreatment with its attendant risks of superinfection and antibiotic toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When therapy is given, antimicrobial selection should be based upon risk factors for multidrug-resistant (MDR) pathogens, including recent antibiotic therapy (if any), the resident flora in the hospital or intensive care unit (ICU), the presence of underlying diseases, and available culture data (interpreted with care). For patients with risk factors for MDR pathogens, empiric broad-spectrum, multidrug therapy is recommended. Once the results of pretherapy cultures are available, therapy should be narrowed based upon the susceptibility pattern of the pathogens identified.",
"   </p>",
"   <p>",
"    The importance of providing appropriate therapy at the time of presentation was illustrated in a retrospective study of almost 400 patients with culture-positive HCAP who survived but remained hospitalized 48 hours after hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/6\">",
"     6",
"    </a>",
"    ]. Mortality was significantly higher among the 107 patients who received inappropriate initial therapy compared with the 289 patients who received appropriate coverage (30 versus 18 percent); switching to an appropriate regimen did not reduce the risk of death.",
"   </p>",
"   <p>",
"    In a study that assessed the microbial prediction and validated the adequacy of the 2005 American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    guidelines for HAP in the ICU, adherence to the guidelines resulted in more adequate treatment and a trend toward a better clinical response in patients who presented late (&ge;5 days) or had risk factors for drug-resistant bacteria, but did not affect mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/7\">",
"     7",
"    </a>",
"    ]. The 2005 guidelines were worse than the 1996 guidelines for predicting drug-resistant bacteria; this was mostly observed for cases classified as lower risk for multidrug-resistant pathogens (ie, early onset infection without specified risk factors for resistant infection), suggesting that such patients may in fact be at risk for resistant pathogens.",
"   </p>",
"   <p>",
"    In a survey of physicians at academic medical centers, respondents selected guideline-concordant antibiotic regimens only 9 percent of the time for HCAP compared with 78 percent of the time for CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/8\">",
"     8",
"    </a>",
"    ]. A retrospective study showed that HCAP is associated with more severe disease, longer hospital stay, and higher mortality rates than community-acquired pneumonia (CAP), and that the use of antimicrobial therapy not recommended by the",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines was associated with increased mortality in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/9\">",
"     9",
"    </a>",
"    ]. Another observational study found that lack of adherence to a VAP protocol (which included considerations of appropriate use and duration of antibiotics) resulted in longer duration of therapy, ventilation, and length of ICU stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an observational study that included 303 patients at risk for MDR pathogens, 28-day mortality was higher among patients who were treated according to the",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines compared with patients whose treatment did not comply with the guidelines (34 versus 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/11\">",
"     11",
"    </a>",
"    ]. The primary reason for &ldquo;non-compliance&rdquo; was lack of a second drug for gram-negative pathogens. Criticisms of this study include the observation that lower coverage for certain MDR pathogens occurred in the compliant group (but was not commented upon by the authors), lack of assessment of the impact of timing of antimicrobial therapy, lack of appropriate adjustment for risk of death, disregard of the impact of treatment deescalation on the classification of compliance, and the possibility that excess mortality may have been at least partly due to toxicity when a triple regimen is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, although the authors attempted to control for higher severity of infection observed in the compliant group, the results may still have been confounded by patients in the compliant group who were at greater risk of poor outcomes at presentation.",
"   </p>",
"   <p>",
"    Potential messages from this study are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians who are following patients and are aware of pathogen and susceptibility patterns within a specific unit may be better able to appropriately select empiric therapy based on individual clinical judgment rather than using routine combination therapy (guidelines are meant to supplement clinical judgment, not supplant judgment).",
"     </li>",
"     <li>",
"      The need for two-drug therapy is not necessary in many cases of gram-negative infection.",
"     </li>",
"     <li>",
"      The definition of risk for MDR as stated in the 2005 guidelines is not precise, particularly for HCAP, and should be readdressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various editorials and studies have reported that it is an overgeneralization to consider all HCAP patients at increased risk for MDR pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The challenge for clinicians is to correctly identify the HCAP patient who is most likely to benefit from empiric treatment with broad-spectrum antibiotics with activity against MDR pathogens. The definition of HCAP is being reevaluated, and future investigations are required to better define patients with HCAP who are likely to be infected with MDR pathogens. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gram-negative pathogens'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Multidrug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given the concerns about the lack of precision of the definition of HCAP for detecting patients infected with resistant organisms, a validation study of a clinical scoring system for predicting resistant bacteria was performed, which compared the definition of HCAP to the scoring system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk score was calculated using the following weighted points:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent hospitalization of at least 48 hours during the preceding 90 days &ndash; 4 points",
"     </li>",
"     <li>",
"      Residence in a nursing home &ndash; 3 points",
"     </li>",
"     <li>",
"      Chronic hemodialysis &ndash; 2 points",
"     </li>",
"     <li>",
"      Critical illness &ndash; 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk score was higher in patients with pneumonia caused by a resistant pathogen than in those without a resistant pathogen (median score 4 versus 1) and was more accurate than the definition of HCAP for detecting patients with pneumonia caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and extended-spectrum beta-lactamase producing gram-negative bacilli. A risk score &gt;0 had a negative predictive value of 85 percent; thus, a risk score of 0 could lead to fewer patients unnecessarily receiving broad-spectrum antibiotics if it is used to guide the choice of therapy. Another study of patients requiring hospitalization for pneumonia who came from the community found that hospitalization in the preceding 90 days (odds ratio [OR] 4.87, 95% CI 1.90-12.4) and residency in a nursing home (OR 3.55, 95% CI 1.12-11.24) were independent predictors of infection with a resistant pathogen; these factors were also independent predictors of in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective analysis of local microbiologic data on HAP pathogens from 111 consecutive patients in 2004, investigators developed institution-specific treatment guidelines in order to improve empiric antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/19\">",
"     19",
"    </a>",
"    ]. Institution guideline-directed treatment regimens were predicted to provide adequate initial therapy for &gt;90 percent of patients who develop HAP &ge;10 days after hospitalization (eg, those at greatest risk of multidrug resistant pathogens). In this institution, use of a fluoroquinolone per the national guidelines, would not have provided adequate additional antimicrobial activity for the beta-lactam resistant gram-negative bacilli (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    was active against &lt;10 percent of these pathogens which were also resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ). This study illustrates the importance of using local susceptibility data to develop treatment guidelines.",
"   </p>",
"   <p>",
"    The implementation of recommendations to assess a patient's status 72 hours after the initiation of therapy and to discontinue antibiotics or narrow the regimen (deescalate therapy) based upon appropriate culture results may reduce the selective pressure for antimicrobial resistance.",
"   </p>",
"   <p>",
"    A prospective observational study of 398 intensive care unit (ICU) patients with suspected VAP found that mortality was significantly lower among patients in whom therapy was deescalated compared to those whose therapy was either escalated or unchanged (17 versus 43 and 24 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/20\">",
"     20",
"    </a>",
"    ]. The study was limited because of its observational nature; confirmation of these results awaits a randomized controlled study. In another study, deescalation was evaluated in surgical patients with septic shock in a retrospective evaluation of 138 patients with VAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/21\">",
"     21",
"    </a>",
"    ]. Deescalation of antimicrobial therapy occurred in 55 percent of patients who had received initial therapy effective against the identified pathogen (most common initial choice was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ). The mortality rate of patients who underwent deescalation therapy was 35 percent compared with 42 percent among patients who did not have deescalation, a difference that did not reach statistical significance. This study demonstrated that deescalation therapy did not lead to recurrent pneumonia or increased mortality in this population of critically ill surgical patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific antimicrobial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In critically ill patients, in those receiving antibiotics prior to the onset of pneumonia, and in institutions where these pathogens are frequent, coverage of methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and antibiotic-resistant gram-negative bacilli, such as Acinetobacter spp, and Legionella should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Methicillin-resistant Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;If MRSA is a frequent nosocomial pathogen in the institution,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is a necessary first choice for anti-staphylococcal coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ], but should be discontinued if MRSA is not isolated.",
"   </p>",
"   <p>",
"    An overview of the treatment of invasive MRSA infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41849380\">",
"    <span class=\"h4\">",
"     Linezolid and vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , with variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of nine randomized trials that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (in seven trials) or teicoplanin (in two trials) for nosocomial pneumonia found no differences in rates of clinical cure or microbiologic eradication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, no differences in clinical cure or microbiologic eradication were observed in the subgroup analysis of patients with MRSA. Linezolid was associated with a higher risk of thrombocytopenia (relative risk [RR] 1.93, 95% CI 1.30-2.87) and gastrointestinal events (RR 2.02, 95% CI 1.10-3.70), but there was no difference in the risk of renal dysfunction.",
"     </li>",
"     <li>",
"      Another meta-analysis, which included eight trials that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or teicoplanin for the treatment of suspected MRSA pneumonia, found no differences in clinical success, microbiologic success, or mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It should be noted that the studies included in the meta-analyses described above used a dosing regimen for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      that is significantly lower than what is recommended by the ATS and the IDSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,23,26,27\">",
"       2,23,26,27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H423214470\">",
"       'Dosing and vancomycin troughs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a later randomized double-blind trial that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      for the treatment of HAP or HCAP due to proven MRSA, the end of study success rate was 58 percent for linezolid and 47 percent for vancomycin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/28\">",
"       28",
"      </a>",
"      ]. Among patients who had a respiratory specimen available for culture at the end of treatment, 16 of 92 patients (17 percent) who received linezolid had cultures that were persistently positive for MRSA compared with 50 of 109 patients (46 percent) who received vancomycin. In this study, vancomycin dosing was adjusted to achieve target trough levels. Linezolid was non-inferior and statistically superior to vancomycin in end of treatment clinical outcome, and microbiologic outcome at end of treatment and end of study, but there were no differences in all-cause 60-day mortality or overall adverse events. Nephrotoxicity occurred more commonly with vancomycin than linezolid (18 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423214470\">",
"    <span class=\"h5\">",
"     Dosing and vancomycin troughs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    failure might be related to suboptimal dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, a trough level of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is targeted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]. However, subsequent studies failed to confirm that higher vancomycin trough concentrations correlate with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. On the other hand, higher vancomycin MICs themselves may be associated with worse outcomes in patients with HAP due to MRSA. This was suggested in a prospective cohort study of 95 patients with MRSA HCAP who were treated with vancomycin in which the targeted trough vancomycin concentration was at least four times the MIC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/30\">",
"     30",
"    </a>",
"    ]. High MIC (&ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    strains of MRSA were detected in 54 percent of patients. Despite achieving the target trough concentration, mortality was higher among patients whose MRSA strain had a high MIC than patients whose MRSA strain had a low MIC (24 versus 10 percent). In a later prospective study that included 158 patients in the ICU with HAP, VAP, or HCAP, an increase in 28-day mortality was observed in patients whose MRSA isolates had increased MICs; an increase in mortality occurred as the vancomycin MIC increased from 0.75 to 3",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    and was present even for strains within the susceptible range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    treatment guidelines on HAP, VAP, and HCAP; the 2011 IDSA guidelines for the treatment of MRSA infections; and a 2009 United States pharmacy consensus review recommend target",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,23,26,27\">",
"     2,23,26,27",
"    </a>",
"    ]. However, these recommendations are based on retrospective pharmacokinetic modeling in the absence of prospective clinical data.",
"    <span class=\"nowrap\">",
"     PK/PD",
"    </span>",
"    analysis has suggested that lung vancomycin AUC:MIC &gt;400 may be difficult to achieve (particularly for isolates with MIC &gt;1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Clinical data have failed to demonstrate a relationship between treatment outcome and target troughs of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines on HAP, VAP, and HCAP and the 2011 IDSA guidelines for the treatment of MRSA infections recommended either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for infections suspected or proven to be due to MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. It was noted that linezolid might be preferred in patients at risk for or with renal insufficiency in whom vancomycin is often underdosed and is associated with a risk of nephrotoxicity. Linezolid also may reduce toxin production, although the possible benefit of this has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Linezolid is particularly preferred in hospitals in which a substantial proportion of MRSA isolates have a vancomycin MIC &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Linezolid resistance and linezolid failure have been described rarely. An alternative to linezolid and vancomycin is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg IV or orally three times daily), provided that the isolate is known to be susceptible, although there are fewer data to supports its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Linezolid resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link&amp;anchor=H17417169#H17417169\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Linezolid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual doses are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      &ndash; 600 mg twice daily IV (or orally if or when the patient is able to receive oral medications).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &ndash; 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (based on actual body weight) IV every 8 to 12 hours for patients with normal renal function, with a target serum trough concentration of 15 to 20",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      In seriously ill patients, a loading dose of 25 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be used to facilitate rapid attainment of the target trough concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link\">",
"       \"Vancomycin dosing and serum concentration monitoring in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41849395\">",
"    <span class=\"h4\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been interest in using other agents for the treatment of MRSA pneumonia, but none of the following agents can be recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       Daptomycin",
"      </a>",
"      <strong>",
"       cannot",
"      </strong>",
"      be used to treat pneumonia because it does not achieve sufficiently high concentrations in the respiratory tract.",
"     </li>",
"     <li>",
"      Data are limited on the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      . In a randomized trial of HAP that included 38 patients with MRSA pneumonia, there was a nonsignificant lower rate of clinical success with quinupristin-dalfopristin compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (31 versus 44 percent) and a higher rate of adverse effects that led to discontinuation of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       Ceftaroline",
"      </a>",
"      is a broad-spectrum cephalosporin with activity against MRSA, which has been approved by the US Food and Drug Administration (FDA) for CAP, but not for CAP caused by MRSA, or for HAP, VAP, or HCAP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"       Tigecycline",
"      </a>",
"      is a broad-spectrum antibiotic with activity against MRSA. In September 2010, the FDA issued a safety announcement regarding an increased mortality risk associated with the use of tigecycline compared with that of other drugs that was observed in a pooled analysis of 13 trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/40\">",
"       40",
"      </a>",
"      ]. The increased risk was seen most clearly in patients treated for HAP, particularly VAP. In a randomized trial of 945 patients with HAP, tigecycline with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      was compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"       imipenem-cilastatin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/41\">",
"       41",
"      </a>",
"      ]. In the clinically evaluable population, the cure rate for tigecycline was significantly lower than for imipenem (68 versus 78 percent). Cure rates in clinically evaluable patients with VAP were 48 percent for tigecycline and 70 percent for imipenem. Cure rates for MRSA infection (HAP and VAP) were 44 percent for tigecycline and 77 percent for imipenem plus vancomycin.",
"      <br/>",
"      <br/>",
"      A 2012 meta-analysis of 10 published and 3 unpublished randomized noninferiority trials also found that tigecycline was associated with an absolute mortality increase of 0.7 percent (95% CI 0.1-1.2 percent) compared with other agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, tigecycline was associated with an absolute increase in noncure rate of 2.9 percent (95% CI 0.6-5.2 percent). These effects were not isolated to a specific type of infection or comparator antibiotic regimen.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/42/27301?source=see_link\">",
"       Telavancin",
"      </a>",
"      is an antibiotic with activity against MRSA. In two randomized trials (the ATTAIN studies), among patients with HAP due to monomicrobial infection with MRSA, the cure rate (regardless of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      MIC) was 82 percent for telavancin and 74 percent for vancomycin (95% CI -3.5-19.3) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/43\">",
"       43",
"      </a>",
"      ]. The cure rate among patients with MRSA with reduced susceptibility to vancomycin (MIC &ge;1",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      was 87 percent in those who received telavancin versus 74 percent in those who received vancomycin (95% CI 0.5-23.0). It is important to note that the dose of vancomycin that was used in these studies was lower than the dose that is currently recommended. Telavancin has not been approved by the FDA for the treatment of pneumonia. Furthermore, it is unavailable globally due to manufacturing problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423214193\">",
"    <span class=\"h3\">",
"     Methicillin-susceptible Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a sputum culture reveals MSSA, empiric therapy for MRSA should be replaced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gram-negative pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although combination antimicrobial therapy for HAP, VAP, and HCAP due to gram-negative pathogens (especially Pseudomonas) is commonly administered, there is no conclusive evidence to support this practice. The best rationale for the use of combination therapy is to provide a greater spectrum of activity when there is risk for MDR pathogens (eg, if the pathogen is resistant to one agent it may be susceptible to the other) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]. Other commonly cited reasons for combination therapy include the potential for synergistic efficacy as well as the potential to reduce the emergence of resistance. However, it is not clear that two agents offer improved outcomes for treating gram-negative pneumonia.",
"   </p>",
"   <p>",
"    A meta-analysis and a subsequent large, randomized trial suggested that monotherapy of VAP was as effective as combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, the percentage of MDR organisms was low in the trials reviewed in the meta-analysis and in the randomized trial. In addition, the randomized trial excluded patients known to be colonized with Pseudomonas or MRSA, and found that combination versus monotherapy was associated with improved adequacy of initial antibiotics and microbiological eradication of infecting organisms in patients who had infection due to Pseudomonas, Acinetobacter, and MDR gram-negative bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, it is difficult to extrapolate the efficacy of monotherapy to ICUs with high incidences of these pathogens.",
"   </p>",
"   <p>",
"    In another study of patients hospitalized in an ICU due to trauma, 84 patients with VAP caused by Pseudomonas were treated with monotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    2 g intravenously every 8 hours); this resulted in microbiologic eradication (based on repeat BAL showing &lt;103",
"    <span class=\"nowrap\">",
"     organisms/mL)",
"    </span>",
"    in 94 percent of patients with no recurrences, suggesting that combination therapy is unnecessary when the initial antimicrobial therapy is active against the isolate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In ICU settings in which extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are found, cephalosporins should be avoided as monotherapy, due to the selection of resistant organisms when these agents are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/48\">",
"     48",
"    </a>",
"    ]. The most reliable agent in this setting is a carbapenem (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"     imipenem-cilastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Legionella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have diabetes mellitus, renal disease, structural lung disease, or have been recently treated with glucocorticoids may require coverage for Legionella spp (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or a fluoroquinolone). HAP and VAP due to Legionella spp are also more common in hospitals where the organism is present in the hospital water supply. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540565903\">",
"    <span class=\"h3\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have aspirated or had recent abdominal surgery may warrant coverage for anaerobes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , beta-lactam-beta-lactamase inhibitor, or a carbapenem). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link&amp;anchor=H7#H7\">",
"     \"Anaerobic bacterial infections\", section on 'Pleuropulmonary infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249925660\">",
"    <span class=\"h3\">",
"     Antiinflammatory effects of macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been interest in the nonantibiotic antiinflammatory effects of macrolides. A randomized trial of 200 patients with sepsis and VAP showed that those who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (in addition to standard treatment including antibiotics) had significantly faster resolution of VAP (10 versus 15.5 days) and weaning from mechanical ventilation (16 versus 22.5 days) compared to those who received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/52\">",
"     52",
"    </a>",
"    ]. Among those who died of sepsis, time to death was significantly prolonged in those who received clarithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Empiric treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with the",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines for the management of HAP, VAP, or HCAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines can be accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     file://www.thoracic.org/statements/",
"    </a>",
"    . Knowledge of the predominant pathogens, and particularly their susceptibility patterns, should greatly impact the choice of empiric therapy; in some cases, the appropriate regimen will differ from the regimens recommended in the",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     No known multidrug resistance risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following intravenous antibiotic regimens for empiric coverage of HAP and VAP in patients with no known risk factors for multidrug-resistant (MDR) pathogens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (2 g intravenously daily).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g intravenously every six hours).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg intravenously daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      (400 mg intravenously daily). When the patient is able to take oral medications, either agent may be administered orally at the same dose as that used for IV administration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"       Ertapenem",
"      </a>",
"      (1 g intravenously daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Choice of a specific agent for empiric therapy should be based on knowledge of the prevailing pathogens (and susceptibility patterns) within the healthcare setting. If there is concern for gram-negative bacilli resistant to the above options (eg, Enterobacter spp, Serratia spp, Pseudomonas spp) based upon microbiologic data at the specific institution, we feel that it is reasonable to initiate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    (4.5 g IV every six hours) or another agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    or a carbapenem) as monotherapy for patients without known risk factors for MDR bacteria provided that the institution&rsquo;s susceptibility data support in vitro activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Known multidrug resistance risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Host risk factors for infection with multidrug resistant (MDR) pathogens include receipt of antibiotics within the preceding 90 days, current hospitalization of &ge;5 days, high frequency of antibiotic resistance in the community or in the specific hospital unit, immunosuppressive disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy, and presence of risk factors for HCAP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'MDR risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455714535\">",
"    <span class=\"h4\">",
"     Traditional dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional dosing of each agent is described in the following discussion, but extended infusions may be considered to optimize pharmacokinetics and pharmacodynamics, especially in critically ill patients. (See",
"    <a class=\"local\" href=\"#H249925799\">",
"     'Extended infusions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with known MDR risk factors, we recommend empiric combination therapy including:",
"   </p>",
"   <p>",
"    <strong>",
"     ONE of the following:",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antipseudomonal cephalosporin such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (2 g intravenously every 8 hours).",
"     </li>",
"     <li>",
"      Antipseudomonal carbapenem such as imipenem (500 mg intravenously every six hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      (500 mg intravenously every eight hours; administered over one hour for HAP or HCAP, administered over four hours for VAP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g intravenously every six hours).",
"     </li>",
"     <li>",
"      For patients who are allergic to penicillin, the type and severity of reaction should be assessed. The great majority of patients who are allergic to penicillin by skin testing can still receive cephalosporins (especially third-generation cephalosporins) or carbapenems. If there is a history of a mild reaction to penicillin (",
"      <strong>",
"       not",
"      </strong>",
"      an IgE-mediated reaction, Stevens Johnson syndrome or toxic epidermal necrolysis), it is reasonable to administer a cephalosporin or carbapenem using a simple graded challenge (eg, give",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      of dose, observe closely for 1 hour, then give remaining",
"      <span class=\"nowrap\">",
"       9/10",
"      </span>",
"      of dose, observe closely for 1 hour). Skin testing is indicated in some situations. If a skin test is positive or if there is significant concern to warrant avoidance of a cephalosporin or carbapenem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      (2 g intravenously every six to eight hours) is recommended. Indications and strategies for skin testing are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"       \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with past allergic reactions to cephalosporins may also be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      , with the possible exception of those allergic to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      . Ceftazidime and aztreonam have similar side chain groups, and cross reactivity between the two drugs is variable. The prevalence of cross-sensitivity has been estimated at &lt;5 percent of patients, based upon limited data. Patients with past reactions to ceftazidime that were life-threatening or suggestive of anaphylaxis (involving urticaria, bronchospasm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension) should not be given aztreonam unless evaluated by an allergy specialist. In contrast, a reasonable approach in those with mild past reactions to ceftazidime (eg, uncomplicated maculopapular rash) would involve informing the patient of the low risk of cross-reactivity and administering aztreonam with a graded challenge",
"      <span class=\"nowrap\">",
"       (1/100,",
"      </span>",
"      <span class=\"nowrap\">",
"       1/10,",
"      </span>",
"      full dose, each separated by 1 hour of observation). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5400?source=see_link&amp;anchor=H209441#H209441\">",
"       \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\", section on 'Use of carbapenems and monobactams'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     PLUS consider adding one of the following (if microbiologic data from the institution or the patient&rsquo;s previous cultures suggest that one of the following agents provides necessary additional coverage for gram-negative bacilli [GNB] in combination with the selected beta-lactam).",
"    </strong>",
"    In light of the results of several studies suggesting comparable outcomes with monotherapy compared with combination therapy of GNB and the potential for added toxicity of the aminoglycosides, it may not be beneficial to add one of the following agents (see",
"    <a class=\"local\" href=\"#H249925653\">",
"     'Approach to therapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antipseudomonal fluoroquinolone, preferred regimen if Legionella is likely, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (750 mg intravenously daily). These agents may be administered orally when the patient is able to take oral medications. The dose of levofloxacin is the same when given intravenously and orally, while the dose of ciprofloxacin is 750 mg orally twice daily.",
"     </li>",
"     <li>",
"      Aminoglycoside such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily); once daily dosing is only appropriate for patients with normal renal function. A single serum concentration should be obtained 6 to 14 hours after the first dose, and the dose should be adjusted as needed based upon the following nomogram (",
"      <a class=\"graphic graphic_figure graphicRef62508 \" href=\"mobipreview.htm?2/62/3054\">",
"       figure 1",
"      </a>",
"      ). The aminoglycoside can be stopped after five to seven days in responding patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/30/8679?source=see_link\">",
"       \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Addition of an alternative agent, such as intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      , may be appropriate if highly resistant Pseudomonas spp or Acinetobacter spp is suspected. In some cases, inhaled colistin may be appropriate as adjunctive therapy in combination with systemic antimicrobials, as discussed below. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of Pseudomonas aeruginosa infections\", section on 'Alternative therapy in multidrug resistant infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=see_link&amp;anchor=H1211132#H1211132\">",
"       \"Treatment and prevention of Acinetobacter infection\", section on 'Nosocomial pneumonia'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1077595\">",
"       'Aerosolized antibiotics'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     PLUS ONE of the following (if MRSA is suspected, there are MRSA risk factors, or there is a high incidence of MRSA locally):",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (600 mg intravenously every 12 hours; may be administered orally when the patient is able to take oral medications)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [based on actual body weight] intravenously every 8 to 12 hours for patients with normal renal function, with a target serum trough concentration of 15 to 20",
"      <span class=\"nowrap\">",
"       mg/L.)",
"      </span>",
"      In seriously ill patients, a loading dose of 25 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be used to facilitate rapid attainment of the target trough concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link\">",
"       \"Vancomycin dosing and serum concentration monitoring in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If patients have recently received antibiotics, empiric therapy should generally be with a drug from a different class since earlier treatment may have selected pathogens resistant to the initial class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249925799\">",
"    <span class=\"h4\">",
"     Extended infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of increasing resistance of pathogens associated with VAP, HAP, and HCAP, one potential strategy to enhance the antimicrobial potential of a given agent is to optimize the pharmacodynamic effect. Based upon the pharmacokinetic and pharmacodynamic properties of each agent, optimization of antimicrobial effect can be achieved with increased doses (for concentration-dependent antibiotics such as aminoglycosides and fluoroquinolones) or with prolonged or continuous infusions (for time-dependent antibiotics such as beta-lactams) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/53\">",
"     53",
"    </a>",
"    ]. Such regimens can potentially provide effective therapy for pathogens with higher minimum inhibitory concentration (MICs), and may impede the emergence of resistance, and potentially provide a pharmacoeconomic benefit. Extended infusions are generally more practical than continuous infusions, since dedicated intravenous catheters are required for continuous infusions.",
"   </p>",
"   <p>",
"    Since the beta-lactams are associated with optimal outcomes when the level of the drug is above the MIC for the pathogen for an appropriate percent of the dosing interval, this effect can potentially be improved with prolonged infusion of the antimicrobial. This has been demonstrated with the use of a 3 to 4 hour infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , or the carbapenems,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    , for the treatment of VAP due to gram-negative bacilli with higher MICs than the usual breakpoints for susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/54-61\">",
"     54-61",
"    </a>",
"    ]. An extended infusion of imipenem is",
"    <strong>",
"     not",
"    </strong>",
"    appropriate, since it does not remain stable for prolonged periods.",
"   </p>",
"   <p>",
"    Dosing guidelines for extended infusions have",
"    <strong>",
"     not",
"    </strong>",
"    been published; we use the following dosing regimens for extended infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    based on",
"    <span class=\"nowrap\">",
"     pharmacokinetic/pharmacodynamic",
"    </span>",
"    modeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/54-61\">",
"     54-61",
"    </a>",
"    ]. For patients with normal renal function, we use the following initial dosing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      &ndash; 4.5 g infused IV over three hours, administered every six hours. An alternative to the extended infusion is to administer piperacillin-tazobactam as a continuous infusion of 18 g IV over 24 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &ndash; 1 to 2 g infused IV over three hours, administered every eight hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"       Doripenem",
"      </a>",
"      &ndash; 1 g infused IV over four hours, administered every eight hours. Of note, this dose is higher than the approved dose that is used in traditional dosing regimens.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &ndash; 2 g infused IV over three hours, administered every eight hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient can be transitioned to traditional dosing if the MIC is low.",
"   </p>",
"   <p>",
"    In a 2013 meta-analysis of observational studies and randomized trials, patients with pneumonia receiving an extended or continuous infusion of a carbapenem (mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    had lower mortality than patients receiving intermittent bolus dosing (Risk Ratio 0.5, 95% CI 0.26-0.96), although there were no differences in clinical cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/62\">",
"     62",
"    </a>",
"    ]. Previously published meta-analyses that included only randomized trials did not detect a difference in mortality between extended infusions and intermittent bolus dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. A possible reason for this difference is that the disease severity in the randomized trials was low, which is reflected by the low mortality rates in these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/66\">",
"     66",
"    </a>",
"    ]. In contrast, many of the patients in the 2013 meta-analysis were critically ill patients with nosocomial pneumonia. Such patients might be more likely to benefit from extended infusions.",
"   </p>",
"   <p>",
"    In a randomized trial of 60 patients with severe sepsis (nearly half of whom had pneumonia) that was published after the 2013 meta-analysis was performed, plasma antibiotic concentrations exceeded the MIC in 82 percent of patients who received a continuous infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    compared with 29 percent of patients who received intermittent bolus dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/67\">",
"     67",
"    </a>",
"    ]. The rate of clinical cure was significantly higher in those who received a continuous infusion compared with those who received intermittent bolus dosing (70 versus 43 percent). There was a non-significant trend towards increased survival to hospital discharge in patients who received a continuous infusion (90 versus 80 percent), but this study was not powered to detect a survival benefit.",
"   </p>",
"   <p>",
"    In a single center study of extended infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    (administered over three hours) for suspected gram-negative infections in critically ill patients, many of whom had pneumonia, there was no advantage compared with intermittent infusion with regard to treatment success, mortality, or length of hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/68\">",
"     68",
"    </a>",
"    ]. The paucity of isolates with elevated MICs in this study may in part explain the lack of benefit of extended infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1077595\">",
"    <span class=\"h4\">",
"     Aerosolized antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    , polymyxin, or aminoglycosides may be considered as potential additional antibiotics in patients with multidrug-resistant (MDR) gram-negative bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. Aerosolization may increase antibiotic concentrations at the site of infection, and may be particularly useful for treatment of organisms that have high MICs to systemic antimicrobial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/74\">",
"     74",
"    </a>",
"    ]. In a randomized trial that included 100 patients with VAP due to gram-negative bacilli (predominantly MDR Acinetobacter baumannii",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Pseudomonas aeruginosa), patients who were treated with a combination of systemic antibiotics and nebulized colistin had a higher rate of favorable microbiologic outcome compared with patients who were treated with systemic antibiotics alone (microbiologic eradication or presumed eradication 61 versus 38 percent), but there was no differences in clinical outcome (51 versus 53 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective case-control study that included 86 patients with VAP due to MDR gram-negative bacilli (predominantly A. baumannii) treated with a combination of IV and aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    compared with IV colistin alone, there was only a trend towards improved rates of clinical cure, pathogen eradication, and mortality in the patients who received aerosolized and IV colistin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/75\">",
"     75",
"    </a>",
"    ]. However, this study may have been underpowered to show a benefit, adequate doses of aerosolized colistin may not have been used, and the difficulty in diagnosing VAP may have biased the results (ie, if patients without VAP were included) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a trial that included 37 patients with VAP due to P. aeruginosa, patients were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    administered intravenously (ceftazidime 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day via continuous infusion for eight days plus amikacin 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for three days) or by aerosolization (ceftazidime 15 mg eight times daily for eight days and amikacin 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for three days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/77\">",
"     77",
"    </a>",
"    ]. Bacterial eradication occurred more often and more rapidly in the patients who received aerosolized antibiotics. However, no significant clinical differences were detected between the treatment groups, which may have been due at least in part to the small number of patients. Clinical success was achieved in 70 percent of the aerosolized antibiotic group and 55 percent of the IV antibiotic group. No antibiotic resistance developed in patients who received aerosolized antibiotics, but three patients who received IV antibiotics developed resistance to ceftazidime. There were three adverse events related to obstruction of the respiratory filter in the aerosolized antibiotic group; one of these resulted in a nonfatal cardiorespiratory arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tailoring the regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the etiology of HAP, VAP, or HCAP has been identified based upon reliable microbiologic methods and there is no laboratory or epidemiologic evidence of coinfection, treatment regimens should be simplified and directed to that pathogen. The choice of specific agents will be dictated by the results of susceptibility testing. It is important to avoid broad-spectrum therapy once a pathogen has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Staphylococcus aureus and gram-negative bacilli are easy to grow in culture. Thus, if these organisms are not isolated from a good quality sputum specimen, coverage for methicillin-resistant S. aureus and multidrug-resistant gram-negative bacilli can be discontinued.",
"   </p>",
"   <p>",
"    Patients who are improving clinically, are hemodynamically stable, and able to take oral medications can be switched to oral therapy. If the pathogen has been identified, the choice of antibiotic for oral therapy is based upon the susceptibility profile for that organism. If a pathogen is not identified, the choice of antibiotic for oral therapy is either the same antibiotic as the intravenous antibiotic, or an agent in the same drug class, which achieves adequate lung penetration when administered orally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy should be based upon the clinical response. The standard duration of therapy in the past was 14 to 21 days in part because of a concern for difficult to treat pathogens (eg, Pseudomonas spp). However, a shorter course could significantly reduce the amount of antimicrobial drugs used in hospitals where the emergence of resistant pathogens is a concern.",
"   </p>",
"   <p>",
"    The following studies found that short course treatment is effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective randomized multicenter trial of 401 patients with VAP compared outcomes following eight versus 15 days of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/78\">",
"       78",
"      </a>",
"      ]. All patients underwent bronchoscopy for quantitative cultures and were empirically treated with a combination of an antipseudomonal beta-lactam plus either an aminoglycoside or a fluoroquinolone. Investigators were encouraged to change the regimen to a pathogen-directed treatment based upon culture results.",
"      <br/>",
"      <br/>",
"      There was no significant difference between patients treated for eight compared to 15 days in mortality or recurrent infection at 28 days; as expected, patients treated for eight days had more antibiotic-free days. Among patients who developed recurrent infections, MDR pathogens were isolated less frequently in those treated for eight days (42 versus 62 percent for those treated for 15 days). However, patients with VAP caused by nonfermenting gram-negative bacilli (eg, Pseudomonas spp) had a higher pulmonary infection recurrence rate when treated for eight versus 15 days (41 versus 25 percent with 15 days of treatment), although mortality was not different. In a subanalysis of 125 patients who had S. aureus isolated as a pathogen, there was no significant difference based on treatment duration (8 or 15 days) for 28-day mortality or VAP recurrence; this was also the case when only VAP caused by MRSA was considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2011 meta-analysis that evaluated 508 patients with VAP showed that a short (seven to eight day) course of antibiotics compared with a longer (10 to 15 day) course increased antibiotic-free days during the 28 days following enrollment (odds ratio [OR] 4.02, 95% CI 2.26-5.78) and reduced recurrence of VAP due to MDR pathogens (OR 0.44, 95% CI 0.21-0.95) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/80\">",
"       80",
"      </a>",
"      ]. However, for cases of VAP due to non-fermenting gram-negative bacilli, pneumonia recurrence was greater after short-course therapy (OR 2.18, 95% CI 1.14-4.16). The majority of the patients included in the meta-analysis derived from the trial described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/78\">",
"       78",
"      </a>",
"      ], and the remainder were from two other smaller studies. An ICU study evaluated clinical outcomes, including duration of treatment, following implementation of a clinical guideline for the treatment of VAP compared with historical controls (patients with VAP treated prior to implementation of the guideline) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/81\">",
"       81",
"      </a>",
"      ]. The clinical guideline group had a shorter duration of antimicrobial therapy and was less likely to have a recurrent episode of VAP.",
"     </li>",
"     <li>",
"      A prospective study evaluated the ability of the Clinical Pulmonary Infection Score (CPIS) to determine the duration of therapy for ICU patients with new pulmonary infiltrates (",
"      <a class=\"graphic graphic_table graphicRef77054 \" href=\"mobipreview.htm?25/31/26108\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/82\">",
"       82",
"      </a>",
"      ]. Patients were included in the study if they had new-onset pulmonary infiltrates and a CPIS &lt;6. The patients were randomized to either a control group (standard therapy) or to the experimental group (intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      400 mg every eight hours for three days).",
"      <br/>",
"      <br/>",
"      The CPIS was reevaluated at three days and in patients with a CPIS &lt;6, antibiotics were discontinued in the experimental group. If the CPIS was &gt;6, ciprofloxacin was continued or antibiotics were changed based upon the microbiologic results. Significantly more patients in the control group received antibiotics beyond three days compared to those in the experimental group (90 compared with 28 percent in the experimental group). In addition to reduced antibiotic use, the experimental group was less likely to have",
"      <span class=\"nowrap\">",
"       colonization/infection",
"      </span>",
"      with resistant organisms (15 compared with 35 percent of patients in the control group) and had a trend towards lower mortality.",
"     </li>",
"     <li>",
"      Another relevant finding in the 2011 meta-analysis described above was that discontinuation strategies using procalcitonin led to a reduction in the duration of therapy without adversely affecting other outcomes, including mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link&amp;anchor=H322876#H322876\">",
"       \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Other diagnostic tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, we recommend that all patients with HAP, VAP, or HCAP should be evaluated after 72 hours of initial empiric antimicrobial therapy. If the patient has improved after 72 hours, and a pathogen is isolated, antimicrobial therapy should be changed to a pathogen-directed regimen based upon the susceptibility pattern. Therapy should generally be continued to complete a total course of 7 days; we would treat up to 15 days if P. aeruginosa were the etiologic agent, and for up to 21 days for MRSA, depending upon the extent of infection and clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/23\">",
"     23",
"    </a>",
"    ]. Based on the study of S. aureus VAP discussed above, 8 days of therapy may be adequate if there is good clinical response early in the course of appropriate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/79\">",
"     79",
"    </a>",
"    ]. If the patient has improved and no pathogen is identified, we would narrow the regimen, discontinuing therapy for Pseudomonas spp and MRSA.",
"   </p>",
"   <p>",
"    If the patient has not improved at 72 hours and a resistant pathogen is identified, therapy should be changed to pathogen-directed treatment based upon the susceptibility pattern. In addition, failure to improve at 72 hours should prompt a search for infectious complications, other diagnoses, or other sites of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite high absolute mortality rates in hospital-acquired (or nosocomial) pneumonia (HAP) patients, the mortality attributable to the infection is difficult to gauge. Many studies have found that HAP is associated with significant excess risk of death. However, many of these critically ill patients die from their underlying disease and not from pneumonia. Case-control studies estimate that the all-cause mortality rate for HAP and ventilator-associated pneumonia (VAP) is in the range of 33 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, a systematic review of randomized trials for the prevention of VAP has estimated that the attributable mortality of VAP is approximately 9 percent (range 3 to 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective cohort study that used a large inpatient database, mortality rates were 10 percent in patients with community-acquired pneumonia (CAP), 19 percent in patients with HAP, 20 percent in patients with healthcare-associated pneumonia (HCAP), and 29 percent in patients with VAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/3\">",
"     3",
"    </a>",
"    ]. In another study, HCAP was associated with a higher in-hospital mortality rate than CAP (18 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variables associated with increased mortality include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2,84-91\">",
"     2,84-91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serious illness at the time of diagnosis (eg, high APACHE score, shock, coma, respiratory failure, ARDS)",
"     </li>",
"     <li>",
"      Bacteremia",
"     </li>",
"     <li>",
"      Severe underlying comorbid disease",
"     </li>",
"     <li>",
"      Infection caused by an organism associated with multidrug resistance (Pseudomonas aeruginosa, Acinetobacter spp)",
"     </li>",
"     <li>",
"      Multilobar, cavitating, or rapidly progressive infiltrates on lung imaging",
"     </li>",
"     <li>",
"      Delay in the institution of effective antimicrobial therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Acute Physiology and Chronic Health Evaluation II (APACHE II) score has been considered the best system to predict mortality in patients with VAP. A group of investigators has developed a simpler scoring system to predict mortality: the IBMP-10 score based on the presence of immunodeficiency; blood pressure &lt;90 mm Hg systolic; multilobar infiltrates; platelet count &lt;100,000; and &gt;10 days in hospital prior to onset of VAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/63/36858/abstract/91\">",
"     91",
"    </a>",
"    ]. Based on a point for each variable, the mortality rates for each score were: 0 to 2 percent; 1 to 9 percent; 2 to 24 percent; 3 to 50 percent; 4 to 67 percent. In a preliminary analysis, the authors indicated that this five-point system was comparable to APACHE-II in its ability to predict mortality in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/1/19474?source=see_link\">",
"       \"Patient information: Hospital-acquired pneumonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the antibiotic treatment regimen for hospital-acquired (or nosocomial) pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP) should be influenced by the patient's recent antibiotic therapy (if any), the resident flora in the hospital or intensive care unit, the presence of underlying diseases, available culture data (interpreted with care), and whether the patient is at risk for multidrug-resistant (MDR) pathogens. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8892772\">",
"    <span class=\"h2\">",
"     Empiric coverage for patients WITHOUT risk factors for MDR pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For empiric coverage of HAP and VAP in patients with no known risk factors for MDR pathogens, we suggest one of the following intravenous antibiotic regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (2 g intravenously daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g intravenously every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg intravenously daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      (400 mg intravenously daily). When the patient is able to take oral medications, either agent may be administered orally at the same dose as that used for IV administration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"       Ertapenem",
"      </a>",
"      (1 g intravenously daily).",
"     </li>",
"     <li>",
"      Choice of a specific agent for empiric therapy should be based upon knowledge of the prevailing pathogens (and susceptibility patterns) within the healthcare setting. If there is concern for gram-negative bacilli resistant to the above options (eg, Enterobacter spp, Serratia spp, Pseudomonas spp) based upon microbiologic data at the specific institution, we feel that it is reasonable to initiate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      (4.5 g IV every six hours) or another agent (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      or a carbapenem) as monotherapy for patients without known risk factors for MDR bacteria provided that the institution&rsquo;s susceptibility data support in vitro activity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'No known multidrug resistance risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8892792\">",
"    <span class=\"h2\">",
"     Empiric coverage for patients WITH risk factors for MDR pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For empiric coverage of HAP, VAP, and HCAP in patients with known risk factors for MDR pathogens, we recommend empiric combination therapy including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       One of the following:",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antipseudomonal cephalosporin such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (2 g intravenously every eight hours)",
"     </li>",
"     <li>",
"      Antipseudomonal carbapenem such as imipenem (500 mg intravenously every six hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      (500 mg intravenously every eight hours; administered over one hour for HAP or HCAP, administered over four hours for VAP)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g intravenously every six hours)",
"     </li>",
"     <li>",
"      For patients who are allergic to penicillin, the type and severity of reaction should be assessed. If a skin test is positive or if there is significant concern to warrant avoidance of a cephalosporin or carbapenem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      (2 g intravenously every six to eight hours) is recommended.",
"     </li>",
"     <li>",
"      Patients with past allergic reactions to cephalosporins may also be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      , with the possible exception of those allergic to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      . Ceftazidime and aztreonam have similar side chain groups, and cross reactivity between the two drugs is variable. The prevalence of cross-sensitivity has been estimated at &lt;5 percent of patients, based upon limited data. Patients with past reactions to ceftazidime that were life-threatening or suggestive of anaphylaxis (involving urticaria, bronchospasm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension) should not be given aztreonam unless evaluated by an allergy specialist. In contrast, a reasonable approach in those with mild past reactions to ceftazidime (eg, uncomplicated maculopapular rash) would involve informing the patient of the low risk of cross-reactivity and administering aztreonam with a graded challenge",
"      <span class=\"nowrap\">",
"       (1/100,",
"      </span>",
"      <span class=\"nowrap\">",
"       1/10,",
"      </span>",
"      full dose, each separated by 1 hour of observation). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5400?source=see_link&amp;anchor=H209441#H209441\">",
"       \"Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics\", section on 'Use of carbapenems and monobactams'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PLUS",
"      </strong>",
"      consider one of the following (if microbiologic data from the institution or the patient&rsquo;s previous cultures suggest that one of the following agents provides necessary additional coverage for gram-negative bacilli in combination with the selected beta-lactam):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antipseudomonal fluoroquinolone, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg intravenously every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (750 mg intravenously daily).",
"     </li>",
"     <li>",
"      Aminoglycoside such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily). The aminoglycoside can be stopped after five to seven days in responding patients.",
"     </li>",
"     <li>",
"      Addition of an alternative agent, such as intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      , may be appropriate if highly resistant Pseudomonas spp or Acinetobacter spp is suspected. In some cases, inhaled colistin may be appropriate as adjunctive therapy in combination with systemic antimicrobials. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of Pseudomonas aeruginosa infections\", section on 'Alternative therapy in multidrug resistant infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=see_link&amp;anchor=H1211132#H1211132\">",
"       \"Treatment and prevention of Acinetobacter infection\", section on 'Nosocomial pneumonia'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1077595\">",
"       'Aerosolized antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PLUS",
"      </strong>",
"      one of the following (if MRSA is suspected, there are MRSA risk factors, or there is a high incidence of MRSA locally):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      (600 mg intravenously every 12 hours; may be administered orally when the patient is able to take oral medications)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [based on actual body weight] intravenously every 8 to 12 hours for patients with normal renal function, with a target serum trough concentration of 15 to 20",
"      <span class=\"nowrap\">",
"       mg/L.)",
"      </span>",
"      In seriously ill patients, a loading dose of 25 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be used to facilitate rapid attainment of the target trough concentration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Known multidrug resistance risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8892810\">",
"    <span class=\"h2\">",
"     Extended infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an alternative to the traditional dosing regimens described above, extended infusions of certain agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    ) may be considered to optimize pharmacokinetics and pharmacodynamics when MDR pathogens are suspected. (See",
"    <a class=\"local\" href=\"#H249925799\">",
"     'Extended infusions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8892817\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical to reducing overuse of antimicrobials, \"deescalation\" of therapy should be considered after 48 to 72 hours of initial therapy, and should be based upon the results of initial cultures and the clinical response of the patient. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Duration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The duration of therapy should be based upon the clinical response. A short duration of therapy (eg, seven days) is sufficient for most patients with uncomplicated HAP, VAP, or HCAP who have had a good clinical response. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Duration'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/1\">",
"      Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. Respir Care 1994; 39:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/2\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/3\">",
"      Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/4\">",
"      Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/5\">",
"      Meduri GU, Johanson WG Jr. International Consensus Conference: clinical investigation of ventilator-associated pneumonia. Introduction. Chest 1992; 102:551S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/6\">",
"      Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008; 134:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/7\">",
"      Ferrer M, Liapikou A, Valencia M, et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010; 50:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/8\">",
"      Seymann GB, Di Francesco L, Sharpe B, et al. The HCAP gap: differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. Clin Infect Dis 2009; 49:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/9\">",
"      Venditti M, Falcone M, Corrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009; 150:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/10\">",
"      Nachtigall I, Tamarkin A, Tafelski S, et al. Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 2009; 37:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/11\">",
"      Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/12\">",
"      Ewig S. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis 2011; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/13\">",
"      Kollef MH. Health care-associated pneumonia: perception versus reality. Clin Infect Dis 2009; 49:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/14\">",
"      Murri R, De Pascale G. The challenge of identifying resistant-organism pneumonia in the emergency department: still navigating on the erie canal? Clin Infect Dis 2012; 54:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/15\">",
"      Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012; 25:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/16\">",
"      Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011; 53:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/17\">",
"      Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/18\">",
"      Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/19\">",
"      Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/20\">",
"      Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/21\">",
"      Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/22\">",
"      Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5:S378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/23\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/24\">",
"      Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/25\">",
"      Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011; 139:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/26\">",
"      Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/27\">",
"      Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/28\">",
"      Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/29\">",
"      Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57 Suppl 2:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/30\">",
"      Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/31\">",
"      Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/32\">",
"      Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/33\">",
"      Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/34\">",
"      Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/35\">",
"      Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008; 14:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/36\">",
"      Bernardo K, Pakulat N, Fleer S, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/37\">",
"      Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/38\">",
"      Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/39\">",
"      File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/41\">",
"      Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/42\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/43\">",
"      Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31.",
"     </a>",
"    </li>",
"    <li>",
"     Astella Pharma US, Inc. VIBATIV (telavancin for injectio) - critical shortage. file://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM284108.pdf (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/45\">",
"      Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/46\">",
"      Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/47\">",
"      Magnotti LJ, Schroeppel TJ, Clement LP, et al. Efficacy of monotherapy in the treatment of Pseudomonas ventilator-associated pneumonia in patients with trauma. J Trauma 2009; 66:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/48\">",
"      Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/49\">",
"      Scheld WM. Developments in the pathogenesis, diagnosis and treatment of nosocomial pneumonia. Surg Gynecol Obstet 1991; 172 Suppl:42.",
"     </a>",
"    </li>",
"    <li>",
"     Rea-Neto A, Niederman M, Prokocimer P, et al. Efficacy and safety of intravenous doripnem versus piperacillin/tazobactam in nosocomial pneumonia [Abstract L-731]. 47th Interscience Conference of Antimicrobial Agents and Chemotherapy. Sept 2007, Chicago.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/51\">",
"      Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/52\">",
"      Giamarellos-Bourboulis EJ, Pech&egrave;re JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/53\">",
"      McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011; 66 Suppl 2:ii25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/54\">",
"      Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/55\">",
"      Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/56\">",
"      Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/57\">",
"      Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007; 27:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/58\">",
"      Shea KM, Cheatham SC, Smith DW, et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009; 43:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/59\">",
"      Crandon JL, Ariano RE, Zelenitsky SA, et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011; 37:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/60\">",
"      Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009; 63:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/61\">",
"      Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010; 68:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/62\">",
"      Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/63\">",
"      Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/64\">",
"      Tamma PD, Putcha N, Suh YD, et al. Does prolonged &beta;-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/65\">",
"      Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/66\">",
"      Drusano GL, Lodise TP. Saving lives with optimal antimicrobial chemotherapy. Clin Infect Dis 2013; 56:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/67\">",
"      Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/68\">",
"      Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother 2013; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/69\">",
"      Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/70\">",
"      Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/71\">",
"      Luyt CE, Combes A, Nieszkowska A, et al. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009; 22:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/72\">",
"      Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009; 29:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/73\">",
"      Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/74\">",
"      Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2005; 3:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/75\">",
"      Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010; 51:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/76\">",
"      Paterson DL, Rogers BA. How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection. Clin Infect Dis 2010; 51:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/77\">",
"      Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/78\">",
"      Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/79\">",
"      Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/80\">",
"      Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011; :CD007577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/81\">",
"      Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/82\">",
"      Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/83\">",
"      Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med 2011; 39:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/84\">",
"      Rello J, Ru&eacute; M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/85\">",
"      Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 Suppl 4:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/86\">",
"      Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/87\">",
"      Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/88\">",
"      Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/89\">",
"      Leroy O, Meybeck A, d'Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/90\">",
"      Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/63/36858/abstract/91\">",
"      Mirsaeidi M, Peyrani P, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score. Clin Infect Dis 2009; 49:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6993 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36858=[""].join("\n");
var outline_f35_63_36858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pneumonia types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multidrug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H249925653\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific antimicrobial considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41849380\">",
"      Linezolid and vancomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H423214470\">",
"      - Dosing and vancomycin troughs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41849395\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H423214193\">",
"      - Methicillin-susceptible Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gram-negative pathogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Legionella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H540565903\">",
"      - Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H249925660\">",
"      - Antiinflammatory effects of macrolides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Empiric treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - No known multidrug resistance risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Known multidrug resistance risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H455714535\">",
"      Traditional dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H249925799\">",
"      Extended infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1077595\">",
"      Aerosolized antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tailoring the regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8892772\">",
"      Empiric coverage for patients WITHOUT risk factors for MDR pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8892792\">",
"      Empiric coverage for patients WITH risk factors for MDR pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8892810\">",
"      Extended infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8892817\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6993|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/62/3054\" title=\"figure 1\">",
"      Aminoglycoside nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/31/26108\" title=\"table 1\">",
"      Clin pulm infect score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5400?source=related_link\">",
"      Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=related_link\">",
"      Colistin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/30/8679?source=related_link\">",
"      Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/1/19474?source=related_link\">",
"      Patient information: Hospital-acquired pneumonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_63_36859="Approach to diagnostic testing for adenovirus";
var content_f35_63_36859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to diagnostic testing for adenovirus based upon the clinical syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested test(s) for adenovirus if diagnosis is necessary*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper respiratory illness",
"       </td>",
"       <td>",
"        Viral culture if available and/or viral antigen assay on respiratory specimen(s) (eg, nasopharyngeal swab or aspirate; throat swab or wash)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidemic keratoconjunctivitis",
"       </td>",
"       <td>",
"        Viral culture and/or adenovirus-specific antigen assay on conjunctival swab or scraping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        Viral culture or PCR of nasopharyngeal aspirate or swab, throat swab, sputum, tracheal aspirate or BAL material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged diarrhea in young children",
"       </td>",
"       <td>",
"        Adenovirus-specific antigen assay on stool specimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"       <td>",
"        Viral culture or PCR of affected sites; quantitative PCR of blood; biopsy if clinically indicated",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCR: polymerase chain reaction; BAL: bronchoalveolar lavage.",
"     <br>",
"      * If there is a potential outbreak or an individual patient has a severe manifestation (to make decisions about antiviral therapy, exclude other treatable infections, determine prognosis, and/or initiate infection control measures).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The appropriate diagnostic tests depend upon the severity and site(s) of infection, as well as the degree of immunocompromise.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36859=[""].join("\n");
var outline_f35_63_36859=null;
var title_f35_63_36860="Partial mainstem bronchial obs";
var content_f35_63_36860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Partially occluded right mainstem bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 193px; height: 149px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maximal expiratory and inspiratory flow-volume loops before (green, 6mm) and after (blue, 9mm) laser treatment in a patient with a right mainstem bronchial obstruction in addition to complete obstruction of the left mainstem bronchus. The diameter of the orifice at the site of maximal obstruction of the mainstem bronchus both before and after treatment is shown in relation to the corresponding flow-volume loop. Note the relatively parallel rightward shift of the descending limb of the maximal expiratory flow-volume curve after treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36860=[""].join("\n");
var outline_f35_63_36860=null;
var title_f35_63_36861="C peptide in prolonged fast";
var content_f35_63_36861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma C-peptide concentrations after a prolonged fast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 314px; background-image: url(data:image/gif;base64,R0lGODlhBQE6AeYAAP///yBzOf8AAICAgAAAAEBAQMDAwBBsNoCzmQAzGSAgIDAwMKCgoHBwcFBQUBAQEODg4LCwsPDw8NDQ0GBgYJCQkP+/v/9/f8fczZC5nP8QEP8/P//w8BA5HP8wMP/Q0P/AwP+goP9gYI+5nP9AQP9wcP+vr/9QUAhpNBhvN/+QkBBwQP/f38DZzR5yOP8gIP+AgAJmM0CMZvD28+Ds5v/g4GCggP/v7xxxOCB5TQxqNVeWav+wsKDGswRnM//PzwBmM/9fXxRuNv9PT+Pt5v+Pj/8vL2Wedp3BqP8fH/H28rnTwS17Rf8PD9Xk2XOng6vKtP9vb0mNXoGwj/+fn0dcTgg2G6CGc4CvjzuEUZ+mk1CWc9Dj2ZC8pgZoNBJtNsjczoCZjBpwNxZuNwpqNDB/T3CpjQ5rNQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAFAToBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6erruQbu7owMBROLEhQFDYMQ7/AAEBUDKkg41G8fhEsS+Blgt4uAQ4eMBhBYqIgCgQYMBkl8SEBQgYcLDkEEIHHAJQMcOzJCaZJhKofvABgYEOFeBEETHBT4SFGQhAYFKNAzoIDAgIOC9hloQECBoAgSJBTtOWhkSQA/g9IjmZEr1wktBaFcEFNeAQc3AVTY2QCCxQJh/12WcjhgQEaJDz4SgADhwYMBPAkt+DsYAoMHBOYZKtp1UFGkhOgCNgpg8IDCABIL0kwAsUqxTetmdNBgwGOLpckuaFpA7imOrSUuZGqgAoG7EwdNuAggAoEKAD4eYtC0kO18G3OnNLo7n2/gmjO3JhCyEMqHrSEAnuqAgIMBC1m6fv2ZZG7Zss33FC9e+OLbhJhSSPpuoFWj7ClH59zaenR/DyzAgEUG2LMaARGIN95cRtWlnnooOWBAYIM8oIAB3dHjHiESOTVIdwrURdVmKl1lIYYE0INYA29JZwhK/cnk3YQTUVDBUr9FmNaCoqT0YHpMBZibbqsp0NWGPiG2Y/9mHMVFoiBXTVBkV4c9wNR0MQ4CIyEWCTkTYlZ61BmPZJZp5plopqnmmmy26eabcMYp55x01mnnnXjmqeeefPbp55+ABjpTXYQOEAYCiCaq6KKMNuroo5BGKumklC7aQp+DFlpAAigc4OmnoIYq6qiklmrqqaimquqnKCAQqEYJHBDArLTWauutuOaq66689urrr7Qe4OqrJMUK7LHIJqvsssEO++oAxjIr7bTUIissscXKWu223HYbwLXEQqutt+SWeyy4z0Zr7rrs4opuoOK2K++87wIa77z4mlvvn/fm6y+3+/rZ778ESxtwnwMXrLC1zsKr7sIQ/3ownwlHbHH/rhPvWfHFHDeL7cYdc5yxniCHbPHIeZZsMsQo46nyygq3fOfLMBMss5001+zvzXXmrDO+PNPp88/yBj3n0ESza7ScSCetb8P2Pux0wUuvIwEDAQ2EFdYMaI1I01N7W3U6Eqz20QMDmU2dImCHDTDUaI4V3ES+OQBAd0sW0rbb1Y6NTtnUKTDfVVd9LTXfQMN9pj0WUicB4ZTJVGhdm46LeL5+n2ObSd0FxBtTwEk+eeWX/5u5OcSpdhsETRG1VyJ7l77s6eY0gFiIgjBQlJFsHy77urSvGfvvDH/sO/HkBq/m8MhLrDjCxzf/tvGWS5/88xRHbz21yqfJ/Pa6do/m//fgu4u9xtqXP/v5JKevfrLin0n++x6H6z79wMZv5vz4618m//Q7gBmoh79t+aAHBCTXDnbAhAAwYQdZIBcSMDAvIeQAW9kqlyCWEIAdAGAE5MIAAOblBQQm0FuDWOAHZzUFDCzhCLMawROkAMInjOAIGEACE6CAASnMaoIYgIIPRSivFFwQgwCkFQCcoAQiHGGFSAAAEpYAABgCQAmCCIAIiUCEK25xVkQYARKaqMURtgsFJpQLAxoDiiTOCgAYeAIcV6gEJzgQABxcIq2I6EEQErGDE8RiGduVghUsaCejcGMA4FjGFTJykRR85CD7OMgnvtAJI/zjulp1yCx9Qv+RjPTgCql4hBEAYAqQ3OMIKUlEU96wi4NcVyFnwI5M1UUBnvQEKCkYACiskAlUVAIS3sjLSa6QiEzAJBczaUZzcZIdycFOIu9XQFzNkiG2FM00q1fNX5GBfXfKJmCo2U1a4WAFtGTITtbJFk6Ik3TlBJYOwDmO5fynjeQsJw6AQIPxXEgQFHCSLvPZTR3YYEG/EQRQthlPX+2zn+P5SAFWMx9RKFJ2BuWRBLrjHa/hk5sNtdVDMXiIi17uDAcdj0dNYVK+uSAGEHUNASgwIoaGFGMpHY/tmlIByFiUoO97KRfKJA+HoMWmN7XVAWSAJu3sbiufBGr5XnopNUVAQqH/aOnUlkrS3oG0oVQ9k14e4oCVckKrSfsCU8W6gJ0ISaCbQCvRfFBVM/0TACy6R1alaj0hrPVMM8WKTgCz16+W84BpsshDBkABu300qbOyoJoetxPgTMCnnZBrzRDb1UVodmWSVROG1pmPnxq2gJxNk2ccksvM8pV4YziimsLE0tf+Do1sksc7oPrYkBqxTYplLVLjiYIutIk6hGJjVE+rvmuyCR+SuJqDtmYXs3LItpd7JpsokJd2MmICiCmAh9RWHcMxF3zOfS5sGlEUqNbtbgiCHXb5pl0/7UYBRbEb5FryzvmGTQzoFBR1DLAarFGmcP09r/Xm+ardxMYox8Fr/0LNq88Av6ooEViNAVh3ocfIV8HNyyixpNQZKu1OuXrzb9JGOicD0HS49BPxnHaTGN66FsS/Y3GdZoLiuKr4ZzKOUwSOMgAbDxTHpXMBPznBARWEgBxMmYgDKlrYAh4gp5j4gAg0IAABPFkcD6AAWQhrWvy9NKaVaPILusxmL4tjIgVwcWvP+mOYHWALl+DBCdrMZwGUIBwTVUB3QlfloMagrpGoQQnW3Oc+iwAc4HXIAqxLZyTzjauR4EAISNDoTnf50eAwAAMwu1xDI5oRWuayp1d9Ag50Iyi+SVEirZCC92GaEWpeta7Z7AFXbwNB4l0AldvYAfodmhF63rWyef/t62xMJMxkzmqx1edXRSia0cvOtgc+oI0FFKUCerXotMtH10NomtPZTjebNcBtbBggQH0hNLGpLdtBpFrd+F53u980gHFvL7W5zrfAu6wBEGBjLUdNpL+ld4AjJnvgEGfzl6kRZYfkTZcLJ14KfJADLSw64iCXeDUos9E5xzXjpUsBCnJwBXSH/OUCUAE14otXk2ui38hT+QpcFQKY+1wAoI5GdyY6YWnnGAU7T2cNfu7zoD9jo50prbhLhwMdJL0QHmA6zJ3ejCH7o8gKR1zVgWCDdBaiBFqHea+fgbvgONboYXPBAciO5kKAIO1qb/YyhhTtTLwT5TCTewxsUPf/qqhE1XgH+dqZIbioCNudkwMM4EMmeBmcuhAj2XPiQ85uZkSzppmdPMeEEAPLM2IkPd885/edDHkkfOo1E4IPTN+IkSxd9avnEc5By/E01v4zWcc9yDUwcWOM9Z6fFH3BVJ4D3ztiJABAu/BDXnxiAGUnvIH9xXTu/EdA/+7Tp/4yFgDXsyofXzpHgNklAX0AID78EP8zMqRi80zsfmFVv7ol2q95+Eec68BwfMOWfPinA0CgfpnQfqnnf/9nfetEAZR2cgXjAgZIeJvQfrfHgBHXautwf/gieBbICe0HAMGngRC3eL3ATqQVdh94AKVXeAlYHtFngoqnd7pgT/WH/wkeqDSld3kXKIPgR4MnyHrksIPlsnG0Fwoj6H5CGHGd1wtYUyhGZn7yUgY+6AlL2H9NKHBPuAvHBxNZVQUZMIZkWIZmeIZoeIZYkAFgYApLCANb6IQG54U3MiENIGhZVX7D8IZxCHLVZws0Bxh9l1l6KAxLKH19CHF/SAsK8Be28x05WAnTlQxL6HKJOHAyhwsR4BkPMAENIG+EuHcyCACWeIkCB4CzkBCgp0uFGAyVaIogh4rZMInI8Iqw2IDeQIvHYIu3eII2iA26aAxL+H69KHAoOIutCAxLWIwhd4yucBjS5AgTsGE+wTURSBLJ+AvLyIzDR4SsgF+JEWbSiP8YLUFebJONvrCN3OiE3qgKCNIRLOIIB2IS74U3sIOOvaCOypYEG9CPGzBwQWABRmAEFhAEwteFrDAR5KcTjTAAVnJgEMlfkQcXolgIHJBuF0AIA5eRG5AEF/CPB7mIpyBsGyF1ibAbQxaR5iGRo4OPvDCCQbhsGwAAFtBlQXABQ2ACJmAEAtAERWABFnABAnCTNimUHOmR/3iTObmTXRYFFmACQ9BlG4CTOtkEF1CQXfaTFkAFPNlpMBALFQCKX5MSnpMPoHOPFUkIMalsM1mTAmABAMACPxCXAsACN3ABRcACbwkAXQaXAsCRMymUcCmXdFkEAFAEJgAAUZmRNzD/l415AwCQBHWJlzegl502h60wje4whYWgFBZBAXzROh72NS7ZEECobm3Zl3wpAHMpADdwA1RwAZLpl3v5lwDQjwAgmKvZmo3ZkwBgArb5jzQZnAKwAT8JmZ72i6jAUcLlCIWjO03RYxpRmjd4mumWmrVZm0ZgAiwAADeQBLTpl4CZm9npl8MpAMPJkehZkxw5BL85BK3ZaC/wCsilTRZFnbkAk+mWBFEAAD/wj+HJlwW5AXC5nb9ZBMg5nrqpmgKQmEOQkVFAnOl5mxmJk93ZaSfwCtDFUviJCyOoAhipkQHaoILAAgZpBN1pAq2poOXJl02QmDdQBF2mnhO6AU0w/5cscKGN9pWu8G4reJ9pOQhwuI4hh5mssFrIx4pBKgiISKQQVwOvQFulEIzFMII84KROCAtAsVuJ1KG3cIhYOnAkAAvHF4mWQKXEsIQkGKb5xqPPWCjSGVdeCoijCAA1QIxsums8MAuXRQpouod1CgBXmqfZ1o6pAGsOwZlyuqRnR6jLFgvApgCPB6TKoKaCwAEl6KidNqaw8GwBZaaSOKe1YKmC8AF4qqlsJn+v4G2/EW55yKiGsICoymcimQrvtgDx1qWwaggiMKt9ZqTW8KeGGKiEgKm+2maykBM/+qqVSqyEYKrHKgAeIAsH0pzMSonOSgiyiqqy6I7EAQABpf+rzfoIveqrmdipRLEUoEoJwuqK2VqsmeqowNoKIaJYb9dGokoLpHoI0IqqyrkKEzABG1VW4oqtkQCimjqf29CuyviuhqCFbJqhnboc6zoJDKuNDmuR2MambuoKKuhd11qLGVsIHyCv1fBO+ToL+6oICMumUBoLEXAWq3gSE5mysrCyigCx66gBycoRpPZJNgupI2sIHLCx68ipsOCQEbCJQXuOu/oIJYulHesKZEaRftq09Dm0h9Cy67insRBN1oqvTwsJOtuLhqoKYJukoTiul1C0RJqLWOsKONsIa3mLSLuwcdsKc9sIQ1qMqoq3YysJpWiKtVoNF5uOWqsIHHD/qn04r8CYtwmZuIpQt4n4DYebj5KrCH17idMKt4FLCYO7hd0arJC7CnsLCYubiB4gAo77uJ9LCZQ7fRpAAiUQAmerDZf7kpnLCJurei9wAjDAAy9rDrlrmqEQumonAioAAv9aDsVbnaFwpzA3u7V7u+nwvPm5u40wqAL3u8E7vP9Tuu6ovY3QpLu2usvbvGSCvR5Kvo0Qr21GvbZ7NOL7Eu7LCNLbZd4rvC5Tv6hwupbAA+mLMP5LHp2lpIrQD9YxIgosFutBFf3QwJQAwDIxsxVMEAwMwRqsJRQhwQzRrlSqiyIcFrQ4XewbGVorrCHsJCUcF5NowgV8C/+QNdVY/11Oe8N6w8I6PJ0c0hInbHiRoMJwNcI9XMRQ4sMxbAtjVR3miJY4bMQ8DMUtfMSYQMFCXFI7HMVUvMU/bAxQIRV04x3wdXFaTJpYnMNovMVcnK9WXIgrnMZqjI1R3MXI8Bj75cR4DMVxLMdxDMNVnMJuPMRZ3MckjMTeEGF3LDqaAheRt8iNvBOjw8iEAsmUI8mAwciU3Mia3MiSsckTacmf/MignMmX7MiVfMqenMqRZ8G2IB+CEGFnqciqPMu0XMu2fMu4nMu6vMuzzMq0ACIiwmGu87MHjA1kCQDQyTvFvMzM3MzO/MzQHM3SPM3UHA3S1TWGMMM7MihkjAnXbP9dCUHMhPDNhgAWduHN1lgIqriZj2AAU6jN4tDE+uAXq5EP10EXniDPWtI5jKDPJOIQJjkJ/nzPalvOEpFLfSEkAb0N9UhzCpVQiCEB+4DMBV0JDZ03i7UIF10IGUFjlrDRWjJg7twIepFLZxnRlquSgxAYFMIADvAA3SyJKs0hkQM7M00IHHamN40SeQGajrAlhcDSQ9INiSwmC0EhDTAYccquNw0lNT2WJlE4hWCPMh3VTz0Bn7o2jQDUhCDUvjwNsFx0Y1wZsgbEnBDWYinViIDW6vwRS90IbC0SGcvVHxJfq6Go1iDMHqYZxIEWxTEA3wEinaDXrxMdLjZTFkz/2AehGRBgNnUhzoyg2C4C2JMRiRNgG2RhH63R177hId+QzF0RHTu1APQQAUVRY54A2pvRHz6iCKrtIgQ91JPw2pph2kZ1jSvNEQsh2ohB2tX828Ad3MI93MRd3MZ93Mid3Mq93Mzd3M4tDDOMzZ6woYOwUKYgD7wVjwAwjbjdVcQRjZigIOfc1ffrnEPNOi1BIc/MOg+wEGDRmTQBFGnhFlohORjiAPTwFlHdFTHrAEUhFjrRAJRmF2sBgZJzVWUFGF2B1fgwEOnh1Eih3s4cYYiAEiFy131Bfn5hHnCx4UWCJb2BXP9dN0xxryjMqoPTGasRIIjBFwHikCHx4ACA/4dGHc1qfc/gQRm+4TlZPRO5QRsKohndcRDC0TmmEaiaIQGakR5LPhG2cRNMARZD4hs7IuHNTBwxAgHrvA+UwRISEVCPnR6yEeSt4R7C8RGFggj78WC7zeZiPhEPzl3k/dUYVBRwwZCEgBI0dde7sQAJ0gBSXgGb+AAyclRNThP/bRsSUhN3gzaRwdpsPtkTsRsS0ogPouQm+RFgDtkYBAEcpQCgaOEl9hQHgqsd0hRbcTYuIgEfAY5Qctp2I46PvtoP0uQLAZ2+nR624VPHR+fMrCA27euKsBucbgm45NzAPpbCngheBwqPs+zPHe3SPu3UXu3Wfu3Ynu3avu3c3hnt3v7t4B7u4j7u5F7u5n7u6J7u6r7uvxAIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma glucose and C-peptide concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma C-peptide concentration above 0.2 nmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Service, FJ, N Engl J Med 1995; 332:1144.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36861=[""].join("\n");
var outline_f35_63_36861=null;
var title_f35_63_36862="Contents: Pediatric toxicology";
var content_f35_63_36862=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric toxicology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric toxicology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/57/36759\">",
"           Amanita smithiana mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/28/10698\">",
"           Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/33/8730\">",
"           Arsenic exposure and poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/43/24248\">",
"           Bites of recluse spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15337\">",
"           Button and cylindrical battery ingestion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/19/11577\">",
"           Carbamazepine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10345\">",
"           Carbon monoxide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/23/4473\">",
"           Caustic esophageal injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41096\">",
"           Ciguatera fish poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22186\">",
"           Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1786\">",
"           Clinical manifestations and evaluation of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/10/29865\">",
"           Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22313\">",
"           Clonidine and related imidazoline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/18/7466\">",
"           Cyanide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/1/37913\">",
"           Decontamination of poisoned children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1784\">",
"           Designer drugs of abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/60/17353\">",
"           Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2615\">",
"           Dextromethorphan poisoning: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/13/25817\">",
"           Digitalis (cardiac glycoside) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/32/23043\">",
"           Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/5/2137\">",
"           Ethanol intoxication in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/5/23639\">",
"           Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/5/27736\">",
"           Hydrocarbon poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33753\">",
"           Inhalant abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7191\">",
"           Isoniazid (INH) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/62/40935\">",
"           Ketamine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/60/43974\">",
"           Management of ibuprofen poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42615\">",
"           Management of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/18/40233\">",
"           Management of toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/31/25081\">",
"           Bites of widow spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21560\">",
"           MDMA (ecstasy) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/29/474\">",
"           Methamphetamine intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/40/20103\">",
"           Opioid withdrawal in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/35/570\">",
"           Phencyclidine (PCP) intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41863\">",
"           Phenytoin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/41/19098\">",
"           Salicylate poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/22/32104\">",
"           Scorpion stings in the United States and Mexico",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43320\">",
"           Second generation (atypical) antipsychotic medication poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/63/16376\">",
"           Serotonin syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/5/40022\">",
"           Strychnine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-39C648ECA3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_63_36862=[""].join("\n");
var outline_f35_63_36862=null;
var title_f35_63_36863="Tanner staging breasts";
var content_f35_63_36863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Tanner staging of breast development in girls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage 1: Prepubertal.",
"    <br>",
"     Stage 2: Breast bud stage with elevation of breast and papilla; enlargement of areola.",
"     <br>",
"      Stage 3: Further enlargement of breast and areola; no separation of their contour.",
"      <br>",
"       Stage 4: Areola and papilla form a secondary mound above level of breast.",
"       <br>",
"        Stage 5: Mature stage with projection of papilla only, related to recession of areola.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_63_36863=[""].join("\n");
var outline_f35_63_36863=null;
